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1. ABSTRACT 
 
Mutations in the TP53 gene occur in over 50% of the human cancers and most of 
them are missense mutations that result in the expression of mutant forms of p53. 
In addition, p53 mutated proteins acquire new biological properties referred as 
gain-of-function (GOF) that contribute to the induction and maintenance of 
cancer. Autophagy is an intracellular degradative process by which damaged 
macromolecules and organelles are targeted to lysosomes via autophagic vesicles 
and it is crucial to maintain primary biological activities during cellular stresses, 
such as nutrient starvation. Reactive oxygen species (ROS) are highly reactive 
byproducts of mitochondrial oxidative phosphorylation and are implicated in a 
plethora of biological events addressed to sustain each aspect of human cancer 
being able to act as second messengers in cellular signaling. The aim of this thesis 
was to dissect the molecular mechanisms by which oncogenic mutant p53 proteins 
promote cancer cell proliferation and chemoresistance in cancer cells by altering 
crucial signaling pathways involved in autophagy and redox homeostasis. We 
unveiled that GOF mutant p53 proteins, contrarily to its wild-type p53 
counterpart, inhibit the autophagic pathway and enhance mitochondrial ROS in 
cancer cells, leading i) antiapoptotic effects, ii) proliferation and iii) 
chemoresistance of pancreas and breast cancer cells. We found that mutant p53 
significantly counteracts the formation of autophagic vesicles and their fusion 
with lysosomes throughout the repression of some key autophagy-related proteins 
and enzymes with the concomitant stimulation of mTOR signaling. Consequently 
to the deregulation of AMPK signaling, the expression of its effector PGC-1α was 
also affected, driving a reduction of the antioxidant UCP2 protein expression and 
an increase of mitochondrial superoxide that acts as a critical mediator of 
oncogenic proprieties of mutant p53. As a paradigm of this mechanism, we 
showed that atg12 gene repression was mediated by the recruitment of the p50 
NF-kB/mutant p53 protein complex onto two regions of the atg12 promoter 
suggesting the involvement of the p50-p50 homodimer as a transcriptional 
repressor of mutant p53 target genes. We have further correlated the low 
expression levels of the autophagic genes (atg12, becn1, sesn1, and dram1) with 
reduced relapse free survival (RFS) and distant metastasis free survival (DMFS) 
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of breast cancer patients carrying TP53 gene mutations conferring a prognostic 
value to this mutant p53- and autophagy-related signature. Intriguingly, we 
demonstrated that mutant p53-driven mTOR stimulation, beyond its role on 
autophagy repression, sensitize cancer cells carrying mutant TP53 gene to the 
treatment with the mTOR inhibitor everolimus. The data reported in this thesis 
reveal novel mechanisms by which mutant p53 sustains tumor progression and 
lightened on the importance that play the redox cellular status and autophagy 
regulation in the human tumors carrying oncogenic mutant p53 proteins. 
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2. SOMMARIO 
 
 
Mutazioni nel gene TP53 occorrono in oltre il 50% dei tumori umani e la maggior 
parte di loro sono mutazioni missenso che causano l’espressione di isoforme 
mutanti di p53. Inoltre, proteine p53 mutanti acquisiscono nuove proprietà 
biologiche chiamate gain-of-function (GOF) le quali contribuiscono alla sviluppo 
della patologia neoplastica. L’autofagia è un processo degradativo intracellulare 
attraverso il quale macromolecole e organelli citosolici danneggiati sono trasferiti 
ai lisosomi attraverso vescicole autofagiche. L’autofagia è un fenomeno biologico 
cruciale nel mantenere una corretta attività biologica durante vari stress cellulari, 
in particolare la deprivazione di nutrienti. Le specie reattive dell’ossigeno (ROS) 
sono sottoprodotti del metabolismo cellulare altamente reattivi ed agendo come 
secondi messaggeri nel “signaling” intracellulare sono implicati in una vastità di 
eventi che promuovono la tumorigenesi e la progressione tumorale. Lo scopo di 
questa tesi è stato quello di identificare i meccanismi molecolari attraverso i quali 
proteine p53 mutanti promuovono la proliferazione e la chemioresistenza delle 
cellule tumorali in seguito ad un’alterazione di vie di segnalazione intracellulari 
coinvolte nella regolazione nell’autofagia e dello status redox delle cellule. In 
seguito ai nostri studi abbiamo scoperto che la GOF di proteine p53 mutanti, a 
differenza alla loro controparte “wild-type”, inibisce il processo autofagico ed 
incrementa le ROS mitocondriali nelle cellule tumorali, risultando in un effetto 
antiapoptotico, iperproliferativo e di chemioresistenza in cellule tumorali di 
pancreas e mammella. Abbiamo dimostrato che la proteina p53 mutante contrasta 
in maniera significativa la formazione di vescicole autofagiche e la loro fusione 
con i lisosomi attraverso la repressione di alcune proteine ed enzimi chiave del 
processo autofagico e promuove concomitantemente la stimolazione del 
“signaling” di mTOR. Come conseguenza della disregolazione del “signaling” 
dell’AMPK, anche l’espressione del suo effettore PGC-1α risulta inibita, 
provocando una riduzione dell’espressione della proteina disaccoppiante 
mitocondriale UCP2, la quale ha una nota funzione antiossidante. Questo causa un 
incremento di superossido mitocondriale, il quale funge da mediatore chiave delle 
proprietà oncogeniche della proteina p53 mutante. Come paradigma di questo 
7 
 
meccanismo, abbiamo mostrato che la repressione del gene atg12 dipende dal 
reclutamento del complesso proteico p50 NF-kB/p53 mutante su due regioni del 
promotore di atg12 stesso suggerendo il coinvolgimento dell’omodimero p50-p50 
come repressore della trascrizione di geni target di p53 mutante. In seguito, 
abbiamo correlato i bassi livelli di espressione di alcuni geni autofagici (atg12, 
becn1, sesn1, and dram1) con la ridotta sopravvivenza libera da malattia (RFS) e 
libera da metastasi distanti (DMFS) di pazienti affetti da tumore al seno che 
esprimono la mutazione nel gene TP53, la quale conferisce un forte valore 
prognostico ed una firma molecolare autofagica associata all’espressione di p53 
mutante. Al fine di identificare un potenziale approccio terapeutico per i pazienti 
con neoplasie che esprimono p53 mutante, abbiamo dimostrato che la 
stimolazione della via di “signaling” mTOR indotta da p53 mutante, oltre a 
reprimere il macchinario autofagico, sensibilizza anche le cellule tumorali al 
trattamento con everolimus, un inibitore farmacologico di mTOR. Nel complesso, 
i dati riportati in questa tesi rivelano nuovi meccanismi con cui p53 mutante 
sostiene la progressione tumorale e sottolineano l’importanza che riveste lo status 
ossidativo e la regolazione dell’autofagia nei tumori umani che esprimono 
proteine oncogeniche p53 mutanti. 
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3. INTRODUCTION 
Cancer is a complex set of diseases characterized by drastic alterations in the cell 
metabolism and by dynamic changes in the genome that allow the cells to bypass 
the regulatory pathways that orchestrate normal cell proliferation and tissue 
homeostasis. However, despite many individual differences, all human tumors 
share common features, such as i) self-sustained proliferative abilities, ii) 
insensitivity to growth inhibitors and apoptosis, iii) unlimited replicative potential, 
iv) sustained angiogenesis, and v) the capability to invade surrounding tissues and 
metastasize (Hanahan and Weinberg, 2000). Importantly, in addition to these 
features, human tumors may take advantage from an inflammatory 
microenvironment (Mantovani, 2009), and by reprogramming cellular metabolism 
to sustain deregulated cell proliferation (Hanahan and Weinberg, 2011). From a 
molecular point of view, tumourigenesis is a multistep process characterized by a 
gradual modification of normal cells into tumours cells and requires specific 
alterations in various cellular processes. In general, these alterations occur in 
proto-oncogenes or in tumour suppressor genes. In the first group there are genes 
like Ras, Myc, Src and erbB2, which once mutated display an enhanced and 
uncontrolled expression and/or activity, thus promoting growth and survival of 
cancer cells. Conversely, tumours need to inactivate tumour suppressor genes like 
p53, Rb or PTEN that would be physiologically activated in stress conditions to 
limit cellular proliferation and survival. (Hanahan and Weinberg, 2000). 
 
3.1 TUMOR SUPPRESSOR p53: THE GUARDIAN OF THE GENOME 
One of the most important signaling pathways that counteract tumour formation 
and progression is the p53 tumour suppressor pathway. P53 is a transcription 
factor, with a modular structure formed by distinct functional domains: i) N-
terminal transactivation domain (amino acid aa 1-73), interacting with the 
transcriptional machinery (Unger, 1993); ii) proline reach domain (aa 63-97), 
required for p53 stabilization; iii) DNA binding domain (aa 93-312), that 
recognizes and binds the responsive element on DNA and proteins that positively 
or negatively affect p53 activity, such as MDM2 or 53BP1 respectively (el-Deiry, 
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1992); iv) oligomerization domain (aa 325-355), essential for tetramer formation 
that represents the active form of p53 (Shieh, 1999) and v) C-terminal regulatory 
domain, containing residues post-translationally modified involved in modulation 
of its stability (Kruse and Gu, 2009) (figure 1). 
 
Figure 1. Multifunctional domains of p53. The p53 monomer consists of various 
multifunctional domains (Robbins and Zhao 2011). 
 
After more than thirty years of researches, extensive studies envision p53 at the 
centre of a highly interconnected network that conveys and transduces 
biochemical signals deriving by stress conditions. These signals may strongly 
compromise genomic stability and promote neoplastic transformation and can 
originate from external factors, such as γ-rays, UV light, DNA damaging agents 
or chemotherapeutic drugs, as well internal ones, like oncogene activation, high 
levels of reactive oxygen species (ROS), or nutrient deprivation (Levine and 
Oren, 2009). In response to these stresses p53 becomes stabilized and activated, 
events that are governed by a refined combination of post-translational 
modifications and interacting protein partners (Kruse and Gu, 2009). (figure 2). 
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Figure 2. The p53 pathway.  The p53–MDM2 feedback loop is the “hub” of the p53 
pathway. Under normal conditions, it maintains constantly low steady-state p53 levels 
and activity. Various stress signals, related in many ways to carcinogenesis, impinge on 
this central loop to release p53 from MDM2-mediated inhibition. This increases p53 
protein levels and activity, inducing drastic phenotypic changes (Levine and Oren, 2009) 
 
One of the most crucial events that occur to p53 following several injuries is its 
escape from the ubiquitination by its major E3 ubiquitin ligase MDM2 and the 
subsequent degradation by the 26S proteasome (Haupt, 1997; Kubbutat, 1997). 
Once activated, p53 acts essentially as a transcription factor and is became able to 
promote the coordinated expression of a plethora of target genes that are the 
executors of p53-induced cellular responses, such as cell cycle arrest, senescence 
or apoptosis (Levine and Oren, 2009). Despite all these activities are believed to 
rely mainly on the ability of p53 to function as a transcription factor, 
transcription-independent activities can also contribute to its apoptotic functions 
(Marchenko, 2007; Moll, 2005). Because of its role as a key integrator in 
translating diverse stress signals into different cellular outcomes, p53 has been 
namely the “guardian of the genome” (Lane, 1992). Moreover, p53 was recently 
found implicated also in the regulation of other cellular processes ranging from 
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metabolism, autophagy, and stemness (Cicalese, 2009; Crighton, 2006; Green and 
Kroemer, 2009; Vousden and Ryan, 2009). However, the main significance of the 
p53 pathway in tumor suppression is strongly highlighted by the observation that 
mutations of the TP53 gene are very frequent in human cancers. Indeed, whereas 
somatic TP53 mutations contribute to sporadic cancer, germline TP53 mutations 
cause a rare type of cancer predisposition known as Li-Fraumeni Syndrome (LFS) 
which is not associated with site-specific tumours, but rather with a variety of 
tumour types occurring at a relatively early age (Li and Fraumeni, 1969). 
Accordingly, pioneering studies have demonstrated that the absence of p53 
predisposes to spontaneous development of neoplastic disease, as observed in p53 
knockout mouse models (Donehower et al., 1992). Furthermore, somatic 
mutations in the TP53 gene are one of the most common alterations in human 
cancers, occurring in more than 50% of cases (Soussi and Wiman, 2007). In the 
other half of tumours, the p53 pathway is functionally restrained because of either 
the amplification of negative regulators, such as MDM2 (Muthusamy, 2006) or 
the inactivation of upstream factors, like Chk2, ATM or p14ARF (Carr, 2006; 
Grochola, 2010; Vahteristo, 2001). Recent studies clearly demonstrated that the 
restoration of p53 levels is able to interfere with tumour progression in vivo: the 
re-expression of p53 in tumours lacking p53 expression triggered a fast and 
massive regression of established tumours caused by induction of p53-dependent 
apoptosis or senescence (Martins, 2006; Ventura, 2007; Xue, 2007).  
 
3.2 ONCOGENIC MUTANT p53 VARIANTS 
Mutations in the TP53 gene are among the most common gene-specific alterations 
in human cancers. The frequency of TP53 gene mutations can vary considerably 
between cancer types, ranging from 10% in haematopoietic malignancies (Peller 
and Rotter, 2003) to 50–70% in ovarian (Schuijer and Berns, 2003), colorectal 
(Iacopetta, 2003), pancreas (Moore, 2003) and head and neck (Blons and Laurent-
Puig, 2003) cancers. Even if inactivation of the TP53 gene may be obtained 
through several types of mutations, including missense and nonsense mutations or 
insertions/deletions of several nucleotides, missense mutations account for more 
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than 70% of them (IARC TP53 Database, www.p53.iarc.fr). As a consequence, in 
the vast majority of tumours with mutations in the TP53 gene, cells express a full-
length mutant form of the protein, which differs from the wild-type counterpart in 
a single amino acid substitution. Both germline mutations and sporadic somatic 
mutations show the same distribution in the TP53 gene (Varley, 2003). Indeed, 
they are not casually dispersed along the whole sequence, but they generally occur 
in some hot-spots located at the region corresponding to the DBD of the protein 
(figure 3). 
 
Figure 3. The distribution of reported missense mutations along the p53 
sequence. A histogram of p53 missense mutations shows that 95% of mutations occur in 
the core domain; six labelled residues are hot-spots for mutation. (Bullock and Fersht, 
2001). 
 
As shown in figure 3, the majority of all missense mutations are found in six 
“hotspot” codons (Hollstein, 1991; Petitjean, 2007). The p53 missense mutations 
can be classified into two main categories according to their effect on the 
thermodynamic stability of the p53 protein (Bullock and Fersht, 2001). These two 
mutation categories are commonly referred to as “DNA‑contact” and 
“conformational” mutations. The first group includes mutations in residues 
directly involved in DNA binding, such as R248Q and R273H. The second group 
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comprises mutations that cause local (such as R249S and G245S) or global (such 
as R175H and R282W) conformational distortions.  
 
 
Biological impact of the TP53 gene mutations 
Unlike other tumor suppressor genes, which are predominantly inactivated by 
deletion or truncation, the missense mutations on p53 cause a strong functional 
impact (figure 4). 
 
Figure 4. Schematic representation of the functional impacts of the TP53 
mutations. LOF (loss of function); DN (dominant-negative effects); GOF (gain of 
function). (Brosh and Rotter, 2009). 
 
First, mutations can abrogate the tumor suppressor function of p53 (a 
phenomenon is called Loss of Function; LOF) resulting in absent activation of 
downstream effector, and loss of normal checkpoint control (Figure 4) (Brosh and 
Rotter, 2009). This loss of function is due to reduction of p53 binding to its 
consensus DNA sequence and, consequently, hampered transcriptional activation 
of p53 target genes (Kato, 2003). Despite loss of function occurs among missense 
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mutants, it is particularly relevant in truncating, splicing and nonsense mutations, 
as well as in gene deletions. If in the same cell also the remaining allele becomes 
mutated or is lost (loss of heterozygosity), such a cell will be totally deprived of 
anticancer protection by p53.  In addition, most of mutant p53  forms are able to 
oligomerize with the wildtype protein encoded by the second allele, inhibiting its 
function, forming a heterotetramer unable to bind DNA (Dominant negative 
Function) (Figure 4) (Brosh and Rotter, 2009). Hence, even if the wild-type allele 
is retained, the cell may be rendered practically devoid of wildtype p53 functions 
through such a mechanism. 
Finally, several mutations were shown to confer new oncogenic functions to 
mutp53 (Gain of Function; GOF), (Figure 5) totally independent on wtp53, and 
actively contribute to various aspects during tumor progression (Aschauer and 
Muller, 2016). 
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Figure 5. Selected oncogenic properties of mutant p53 proteins and their 
underlying mechanisms. Key cancer hallmarks and selected molecules that are 
associated with mutant p53 GOF. Mutant p53 GOF contributes to cancer progression 
through direct interaction with proteins altering their activity or through the 
transcriptional activation or repression of target genes and downstream molecules. 
(Aschauer and Muller, 2016).  
 
 
Malignant transformation 
The first evidence regarding mutant p53 gain of function was obtained in 1993, 
when it was shown that p53 mutants of both human and mouse origin, but not 
their wild-type counterparts, can transform p53-null cells and provide them with 
an increased ability to form colonies in soft agar and tumors in mice (Dittmer, 
1993). Accordingly, experiments performed knocking down mutant p53 in several 
human cancer cell lines, demonstrated that down-regulation of endogenous mutant 
p53 rendered those cells less tumorigenic (Bossi, 2006; Bossi, 2008). Mutant p53 
was shown to cooperate with activated oncogenic Ras in transformation of 
primary mouse embryo fibroblasts (MEFs) (Lang, 2004). This property is due to 
the ability of different p53 mutants to bind and inactivate the p53 family 
members, p63 and p73 (Di Como, 1999; Strano, 2000). The cooperation between 
mutant p53 and oncogenic Ras was described in vivo by using mouse models of 
skin (Caulin, 2007), lung (Jackson, 2005) and pancreatic cancers (Hingorani, 
2005). Such mice exhibited increased tumour formation, accelerated tumour 
progression and elevated rates of metastasis relative to their p53-null counterparts. 
 
 
Chemoresistance, escape from apoptosis and genomic instability 
One distinctive feature of many mutant p53 proteins is their ability to confer an 
elevated resistance to cells for a variety of apoptotic signals. This effect of mutant 
p53 was revealed for the first time by showing that it can suppress c-Myc-induced 
apoptosis in leukemic cells (Lotem and Sachs, 1995). Interestingly, the 
overexpression of various tumour-associated p53 mutants can render cancer cells 
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more resistant to the effect of chemotherapeutic drugs (Blandino, 1999; Fiorini, 
2015), whereas knockdown of endogenous mutant p53 sensitizes cancer cells to 
killing by such molecules (Bossi, 2006). The mutant p53 ability to protect cells 
from chemotherapeutic drugs is due by various ways, including its capability to 
inhibit p73 pro-apoptotic functions (Bergamaschi et al., 2003a). Accordingly, 
short peptides disassembling the mutant p53/p73 complex restore p73 activity and 
re-sensitize cells harboring mutant p53 to chemotherapy (Di Agostino, 2008). 
High NF-E2-related factor 2 (Nrf2) expression has been shown to promote 
resistance to different anticancer drugs in human cancers (Wang XJ, 2008; Niture 
SK and Jaiswal 2013). However, the underlying mechanism of an increase in Nrf2 
expression is not fully understood although some NF-kB and mutant K-ras-
mediated mechanisms have been reported (Rushworth, 2012; Tao, 2014). 
Recently, it has been suggested that mutant p53 may confer cisplatin resistance in 
lung cancer cells via upregulating Nrf2 transcription (Tung, 2015). Importantly, it 
has been demonstrated that mutp53 sustains NF-kB activation in colorectal cancer 
promoting a chronic inflammation status (Cooks, 2013). Since NF-kB can act as a 
powerful inhibitor of apoptotic stimuli, the stimulation of NF-kB signaling may be 
a further mechanism by which mutp53 proteins inhibit the apoptotic signaling. 
A number of study revealed that mutp53 counteracts normal spindle checkpoint 
control, resulting in chromosomal aberration and polyploidy (Gualberto, 1998). In 
addition, mutp53 interferes with DNA repair, by attenuating base excision repair 
(Offer, 1999), by binding topoisomerase I, fostering DNA rearrangements and 
aberrant homologous recombination, but above all it inhibits double strand repair 
system. Mutp53 binds Mre11 preventing its recruitment at level of dsDNA breaks, 
avoiding Rad50-NBS1 binding and thus ataxia teleangectasia mutated (ATM) 
dependent DNA damage activity (Song, 2007). Intriguingly, has been recently 
shown that mutp53 proteins, through the recruitment of mutp53/E2F4 complex 
onto specific regions of BRCA1 and RAD17 promoters, lead to the inhibition of 
their expression, whose derived proteins play a pivotal role in DNA damage repair 
(Valenti, 2015).  
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Stimulation of the Warburg effect 
Cancer is a complex disease characterized by dramatic metabolic alterations, and 
the Warburg effect, also called aerobic glycolysis, is the best known metabolic 
shift that occurs in cancer cells (Hanahan, 2011; Warnurg, 1956). During this 
phenomenon, even under physiological oxygen concentrations, tumour cells adopt 
glycolysis for their energy requirements and undergo both high rate glucose 
uptake and lactate production, as compared with normal cells (Feng, 2010; Levine 
and Puzio-Kuter, 2010). Many studies highlighted that the Warburg effect 
significantly contributes to tumorigenesis and that its impairment could be 
considered as a therapeutic anticancer opportunity (Christofk, 2008; Fantin, 
2006). Recently, it has been clearly demonstrated that mutp53 proteins stimulate 
the Warburg effect, in both cultured cells and mutp53 knock-in mice (Zhang, 
2013) contrary to wtp53, which is known to repress glycolysis and the Warburg 
effect through transcriptional regulation of genes involved in energy metabolism, 
including SCO2, TIGAR, GLS2 and Parkin (Bensaad, 2006; Matoba, 2006; 
Zhang, 2011). This metabolic-related oncogenic function of mutp53 proteins 
mostly occurs by promoting glucose transporter 1 (GLUT1) translocation to the 
plasma membrane through activation of RhoA/ROCK signalling, thus resulting in 
increased cancer cells glucose uptake and, consequently, in increased glycolytic 
rate and lactate production (Zhang, 2013).  
 
Alteration of tumor microenvironment and implication in cancer progression 
Several studies recently reviewed in Cordani, 2016a demonstrated the 
involvement of mutp53 proteins in the regulation of proteins/enzymes/molecules 
secreted by cancer cells and recognized to functionally alter tumour 
microenvironment. Mutp53 proteins trigger the production and release of 
cytokines addressed to stimulate an inflammatory cancer-associated 
microenvironment and concomitantly to repress the immune system. Remarkably, 
stimulation of expression and release of these cytokines by mutp53 proteins are in 
stark contrast to the inhibitory functions of the tumour suppressor wtp53. Another 
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crucial element supporting the motility of tumour cells and their metastatic 
potential is covered by extracellular pH decrease. This phenomenon is mainly 
related to the stimulation by mutp53 proteins of secreted lactate and implies a 
global alteration of metabolism of cancer cells carrying mutant TP53 gene. The 
extracellular acidification is also involved in the stimulation of the activity of 
matrix metalloproteinases (MMPs), which, in turn, promote extracellular matrix 
(ECM) degradation favoring tumour invasion and cancer motility. Furthermore, 
mutp53 proteins are also described to stimulate secretion of VEGF, which is 
conversely inhibited by wtp53. This is likely the main known event to promote the 
pro-angiogenic feature associated to enhanced metastasis of cancer cells bearing 
mutant TP53 gene  
 
Cell migration and invasion 
Although p53 knockout mice are highly tumor prone, these lesions do not 
metastasize frequently nor generally display invasive pathology (Attardi and 
Jacks, 1999). On the contrary, the presence of mutant p53 leads to a marked 
increase in the incidence of highly metastatic carcinomas in various mouse 
models (Doyle, 2010; Heinlein, 2008; Lang, 2004; Liu, 2000). Indeed, another 
aspect of mutant p53 gain of function that has recently emerged is its ability to 
drive cell migration and invasion (Adorno, 2009; Dhar, 2008; Muller, 2009). This 
is achieved by two non-mutually exclusive mechanisms of inhibition of p63 anti-
metastatic functions (figure 6). 
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Figure 6. Mutant p53 promote cell migration and invasion by inhibiting p63. (A) 
Upon TGF-β induction, SMAD2 is phosphorylated and promotes binding of mutant p53 
to p63, alleviating p63-mediated suppression of Sharp-1 and Cyclin G2 to allow for cell 
migration and invasion. (B) p63 inhibits activation of RCP (through transcriptional 
targets that are currently unknown) to prevent α5-β1 integrin and EGFR recycling to the 
plasma membrane. Upon expression of mutant p53, p63 activity is suppressed, resulting 
in enhanced RCP-driven recycling of α5-β1 integrin and EGFR. This activates Rho and 
PKB/Akt to promote cell migration and invasion (Muller, 2011).  
 
Transcriptional regulation of mutant-p53 Gain of Function 
Missense mutation that occurs on p53, especially in DBD disrupts its ability to 
bind p53 consensus. The molecular basis by which mutant p53 regulates its target 
genes involved in different aspects of tumor progression, such as i) proliferation, 
ii) inhibition of apoptosis, iii) chemo-resistance and iv) metabolism is not fully 
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understood. However, it has been shown that changes in interaction with others 
proteins, with transcription factor, but also with proteins that are not directly 
involved in gene expression regulation, drastically affect gene expression (Kato, 
2003). Moreover, accumulating evidences show that many loci missing for wtp53 
responsive elements are directly induced by mutp53, thus suggesting that mutp53 
acquires distinct DNA-binding and transactivation activities. Indeed, a number of 
in vitro evidence shows that mutp53 conserves the ability to bind DNA with high 
affinity. Mutp53, but not wtp53, has been specifically found to bind with high 
affinity to a variety of nuclear matrix attachment region DNA elements (MARs) 
(Weissker, 1992; Will, 1998). Due to the importance of MARs in nuclear 
processes such as gene expression and DNA replication, it is possible to 
hypothesize that this ability of mutp53 to modulate gene expression and DNA 
replication might represent the molecular basis for its oncogenic potential in 
cancer.  
A pivotal mechanism by which mutp53 exerts its gain of function, is the direct 
binding to the transcription factors to enhance or prevent their activities. Among 
them, the interaction of mutp53 with NF-Y results in the activation of genes 
involved in cell cycle promotion, such as cyclins and cyclin-dependent kinases, 
and cancer growth (Di Agostino, 2006). Some researchers identified a lot of 
mutp53 partners, including Sp1, NF-kB, VDR (Stambolsky, 2010), which upon 
their interaction with mutp53 can regulate the expression of their target genes; or 
SREBP, promoting the mevalonate pathway gene expression (Freed-Pastor, 
2012); or Est-1 that is directly involved in MDR1 transcription and chemo-
resistance (Sampath, 2001). Importantly, mutp53 has been demonstrated to bind 
with members of its own family, p63 and p73, preventing their binding to DNA 
responsive elements, thus preventing their anti-metastatic or pro-apoptotic 
activities. Moreover, as previously mentioned, mutp53 can interact with other 
protein non-directly involved in transcription, such as MRE11 (Song, 2007) or 
Topoisomerase1 (Liu, 2011) both resulting in enhanced genomic instability.  
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 3.3 AUTOPHAGY: WHEN CELLS EAT THEMSELVES 
Autophagy is an intracellular degradative process by which damaged 
macromolecules and organelles are targeted by autophagic vesicles to lysosomes 
and then eliminated. Autophagy is crucial to maintain primary biological activities 
during cellular stresses, such as nutrient starvation (Mizushima, 2009). Once 
autophagy is activated, the cellular components are embedded into double-
membrane vesicles (autophagosomes), which fuse with lysosomes to form an 
autophagolysosome structure to degrade its contents by lysosomal hydrolases 
providing a nutrient source to maintain vital cellular activities (Figure 7) 
(Mizushima, 2007; Yang, 2009). 
 
 
Figure 7 Model of various steps of autophagy. Autophagy is a cellular 
catabolic process during which a double isolation membrane engulfs cytoplasmic 
material including proteins and organelles. The membrane forms a vesicle termed 
autophagosome, which fuses with the lysosome to form the autophagolysosome. 
After fusion the inner membrane is lysed and autophagic cargo is digested by the 
lysosomal proteases (Cordani, 2016). 
 
Autophagy requires the activation of a number of autophagy-related genes 
(ATGs), which play a pivotal role in the formation of double-membrane 
autophagosome vesicles and in the stimulation of the autophagy machinery 
(Klionsky, 2007). Under energetic stresses, ATG1 kinase interacts with ATG13 
and ATG17 in order to initiate the phagophore formation in yeast, probably by 
activating the transmembrane protein ATG9 that serves to recruit lipids to the 
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expanding phagophore (Klionsky, 2007). Vesicular protein sorting 34 (Vps34), 
belonging to the class III PI-3 kinases, has been described to play a critical role in 
various cellular membrane-sorting processes. However, when Vps34 interacts 
with Beclin-1 and other autophagy-related proteins, it mediates the phagophore 
formation and autophagy initiation (Backer, 2008). In addition to the formation of 
several protein-protein complexes which are indispensable for the phagophore 
generation and vesicle nucleation on membranes (Mizushima, 2011) the ubiquitin-
like conjugation systems are necessary for certain ATG proteins to execute their 
functions (Figure 7) (Geng, 2008). In particular, the mammalian homologue of 
ATG8, also called LC3B, is expressed as a full-length cytosolic protein that, upon 
induction of autophagy, is proteolytically cleaved by ATG4, a cysteine protease, 
in order to generate LC3B-I. The carboxy-terminal glycine exposed by ATG4-
dependent cleavage is then activated in an ATP-dependent manner by the E1-like 
ATG7 and transferred to ATG3, a different E2-like carrier protein, to generate the 
active isoform LC3B-II. The recruitment and integration of LC3B-II into the 
growing phagophore is dependent on ATG5–ATG12 interaction, favoring the 
binding of LC3B-II on both internal and external surface of autophagosomes, 
where it plays a role in both fusion of membranes and in selecting cargo for 
lysosomal degradation (Figure 7) (Kirkin, 2009).  
The role of autophagy in regulating cancer cell death or survival remains highly 
debated. A number of studies support the idea that constitutive autophagy may 
have a protective role in cancer cells removing damaged organelles or recycling 
misfolded macromolecules. In support of this hypothesis, several studies report 
that autophagy is rapidly upregulated to maintain metabolic homeostasis in cancer 
cells exposed to stressful conditions, such as nutrient deprivation, oxidative stress, 
hypoxia, or in response to therapy (Kondo, 2005). However, it is also well 
established that uncontrolled autophagy can also lead to cell death, called also cell 
death-type II, likely due to excessive degradation of cellular constituents and 
organelles required for homeostasis of the cells. Furthermore, cancer cells are able 
to escape from extensive autophagic cell death resulting in the enhancement of 
radical oxygen species (ROS) production, genomic instability, and tumor 
progression. Hence, the role of autophagy in cancer is highly controversial and it 
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is likely reliant on the tumor type, the stage of neoplasia and the cellular context 
(Kondo, 2005). Several studies indicate that wild-type p53 protein, in order to 
react to genotoxic or environmental stimuli, triggers autophagy in cancer cells 
through various mechanisms, as the stimulation of the nutrient energy sensor 
AMP-activated protein kinase (AMPK), the inhibition of the mammalian target of 
rapamycin (mTOR) by up-regulation of PTEN and TSC1, and the induction of the 
autophagy-related gene DRAM1 (Crighton, 2007). 
 
 
3.4 REACTIVE OXYGEN SPECIES: THE ACHILLES HEEL OF CANCER 
CELLS 
Reactive oxygen species (ROS) are radicals, ions or molecules, which have a 
single unpaired electron in their outermost shell of electrons and for this character, 
they are highly reactive. In cancer cells high levels of ROS can result from 
increased metabolic activity, mitochondrial dysfunction, peroxisome activity, 
increased cellular receptor signaling, oncogene activity, increased activity of 
oxidases, cyclooxygenases, lipoxigenases and thymidine phosphorylase, or 
through crosstalk with infiltrating immune cells (Storz, 2005; Szatrowski, 1991; 
Babio, 1999). In mitochondria, ROS are produced as an inevitable byproduct of 
oxidative phosphorylation (Figure 8). The electron transport chain encompasses 
complexes I-IV and ATP synthase on the mitochondrial inner membrane. 
Superoxide is generated at complexes I and III and released in the intermembrane 
space or in the mitochondrial matrix (Ha, 2011). 
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Figure 8. Oxidative phosphorylation in mitochondrial electron transport chain 
(ETC), and proton leak via uncoupling proteins (UCPs). UCP dissipates 
mitochondrial membrane potential by facilitating proton leak across the inner membrane, 
thereby minimizing superoxide (O2•−) formation from undesirable interaction between 
molecular oxygen (O2) and high-energy electrons (e−) (Ramsden, 2012). 
 
However, in addition to the mitochondria, peroxisomes are other major sites of 
cellular ROS generation (Danse, 2001). In these organelles, superoxide and H2O2 
are generated through xanthine oxidase in the peroxisomal matrix and 
peroxisomal membranes (del Rio, 1992). The production of ROS can be induced 
by hypoxia, metabolic defects, endoplasmic reticulum (ER) stress and oncogenes. 
However, under normal physiological conditions, the intracellular levels of ROS 
are steadily maintained to prevent cells from damage. Detoxification from ROS is 
facilitated by non-enzymatic molecules, including glutathione, flavonoids and 
vitamins A, C and E or through antioxidant enzymes, such as the transcription 
factor NRF2, breast cancer susceptibility 1 (BRCA1), p53, phosphatase and tensin 
homolog (PTEN), ataxia telangiectasia mutated (ATM) and the action of dietary 
antioxidants which specifically scavenge different kinds of ROS (figure 9). 
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Figure 9. Determination of cellular redox status by a balance between levels of ROS 
inducers and ROS scavengers (Gorrini, 2013).  
 
ROS-sensitive signaling pathways are persistently elevated in many types of 
cancers, where they participate in cell growth/proliferation, differentiation, protein 
synthesis, glucose metabolism, cell survival and inflammation (Storz, 2005). 
Reactive oxygen species, particularly hydrogen peroxide, can act as second 
messengers in cellular signaling (Sundaresan, 1995; Colavitti, 2002). H2O2 
regulates protein activity through reversible oxidation of its targets including 
protein tyrosine phosphatases, protein tyrosine kinases, receptor tyrosine kinases 
and transcription factors (Storz, 2005). A great amount of studies has deeply 
unveiled the involvement of ROS as regulators of several cellular pathways, 
including the i) mitogen-activated protein (MAP) kinase/ERK cascade, ii) 
phosphoinositide-3-kinase (PI3K)/ Akt-regulated signaling cascades, as well as 
the iii) IκB kinase (IKK)/nuclear factor κ-B (NF-κB)-activating pathways (Liu 
and Storz, 2010). Oxidative stress-mediated signaling events play exceptional 
relevance in the development and progression of several human cancers (Fiaschi 
and Chiarugi, 2012). Indeed, ROS are involved in a plethora of biological events 
addressed to sustain each aspect of cancer progression, including i) cell cycle 
progression and proliferation, ii) cell survival and apoptosis, iii) genomic 
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instability and mutations, iv) change in energy metabolism, v) cell motility, 
invasion and higher metastatic potential, vi) angiogenesis, vii) escaping from 
immune destruction and viii) maintenance of tumor stemness. A detailed scheme 
showing the mechanistic contribution of ROS in cancer is reported in figure 10 
(Fiaschi and Chiarugi, 2012). 
 
 
Figure 10. ROS play multiple roles in the hallmarks of cancers. Contribution of 
oxidants is indicated for each point (Fiaschi and Chiarugi, 2012). 
 
However, the role of ROS in cancer biology is ambiguous, indeed despite many 
studies attributed to ROS a pivotal role in promoting many events aimed to 
sustain cancer progression, by acting as signaling molecules (figure 10), many 
others have highlighted that a severe increase in ROS can induce cell death 
following a “non-specific” damage of macromolecules such as the irreversible 
oxidation of lipids, proteins or DNA. (Kamata, 1999). Therefore, ROS represent 
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an “Achilles heel” of cancer cells and new therapeutic improvement could be 
reached playing on this sophisticated redox cellular balance. The majority of the 
damaging effects on DNA are due to hydroxyl ions, which are generated via the 
Fenton reaction (Imlay, 1988). In this reaction transition metals such as iron and 
copper donate or accept free electrons during intracellular reactions and use H2O2 
to catalyze free radical formation. Hydroxyl radicals attack DNA rapidly due to 
their high diffusibility which results in formation of DNA lesions including 
oxidized DNA bases, single strand and double strand breaks (Maynard ,  2009). 
DNA adducts are usually removed by either the base excision repair (BER) or the 
nuclear excision repair (NER) pathways (Mitra, 2001). Cells incapable to 
completely repair DNA lesions (i.e. due to deficient DNA repair enzymes) 
undergo apoptosis to ensure these mutations will not be passed on to progeny 
cells. However, under certain circumstances, the cells harboring DNA mutations 
successfully escape programmed cell death, which raises a high chance for 
cancerous growth.  The oxidative modification of proteins by ROS is implicated 
in the etiology or progression of various disorders and diseases. The major 
damage of ROS to proteins is modification in their amino acid residues, resulting 
in altered functions. The oxidized amino acid residues of proteins can influence 
their ability in signal transduction mechanisms (Meng, 2002), as well to impact 
DNA repair efficiency, the fidelity of DNA polymerase during 
replication/synthesis and transcriptional activity, which tightly associates with 
cancer onset. (Storz, 2005; Burhans, 2007). Lipids are others cellular targets of 
ROS attacks. ROS react with polyunsaturated or polydesaturated fatty acids to 
initiate lipid peroxidation (Gardner, 1989). Lipid oxidation generates numerous 
genotoxic molecules such as malondialdehyde, 2-alkenals and 4-hydroxy-2-
alkenals (Burcham, 1998; Catala, 1999). Interestingly, the importance that plays 
ROS-induced lipid peroxidation in human tumor is corroborated by some clinical 
studies, which have shown its potential use as a tumor marker (Lauschke, 2002). 
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Oncogenic properties of mutant p53 alter oxidative status in cancer cells 
A high ROS level is one of the hallmarks of the human cancers. However, 
nowadays very little is known about the regulation of oxidative stress by 
oncogenic mutant p53 proteins. An interesting study elucidates that GOF p53-
R273H mutant interferes with the normal response of human cells to oxidative 
stress (Kalo, 2012). It has been shown that, upon oxidative stress, mutant p53-
R273H attenuates the activation and function of NRF2, a transcription factor that 
induces the antioxidant response, in several human cancer cell lines, highlighting 
the general nature of this phenomenon. This oncogenic propriety of mutant p53 is 
manifested by the decreased expression of some detoxifying enzymes, as NQO1 
and HO-1, and high ROS levels.  
NADPH oxidase enzymes (NOX family) are some powerful intracellular ROS-
generating sources and represent critical mediators of redox signaling (Thannickal 
and Fanburg, 2000). Some studies have indicated that NADPH-oxidase-dependent 
ROS production can alter cell motility or potentiate metastatic progression 
(Schroder, 2007; Sadok, 2008; Sadok, 2009). An intriguing study reported that 
wild type p53 and mutant p53 differentially regulate NOX4 expression and 
activity, corroborating the statement that GOF mutant p53 plays a role in 
promoting high ROS levels in cancer cells. Indeed, it has been found that while 
wtp53 has an inhibitory effect, mutant p53 proteins are able to enhance NOX4 
expression, enhancing in turn ROS levels, which sustain an invasive phenotype of 
cancer cells. 
 
UCP2: a crucial antioxidant player 
Mitochondrial ATP production occurs by coupling the electron transport chain 
(ETC) with the phosphorylation of ADP into ATP, the so-called oxidative 
phosphorylation. These two processes are not always efficiently coupled, mainly 
because of the presence of mitochondrial transporters in the inner membrane, such 
as uncoupling proteins (UCPs). The UCPs belong to the superfamily of anion 
transport carriers of the mitochondrial inner membrane (Hughes, 2008) and some 
of them are involved in thermogenesis and regulation of mitochondrial ROS. 
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While UCP1 tissue expression is localized and abundant in brown adipose tissue 
(BAT), whereas it is involved in the non-shivering thermogenesis activity 
(Enerbäck, 1997). UCP2 has been found in several tissues, including liver, brain, 
pancreas, adipose tissue, immune cells, spleen, kidney, and the central nervous 
system (Donadelli, 2014) and UCP3 is mainly present in the skeletal muscle 
(Boss, 1997). Unlike UCP1, UCP2 and 3 are involved in a number of postulated 
functions in energy regulation, including regulation of insulin secretion (Zhang, 
2001) or ROS production and control of the immune response (Arsenijevic, 
2000). The other two members of the UCP superfamily, UCP4 and UCP5, are 
expressed in a tissue-specific manner and are involved in mitochondrial 
membrane potential reduction (Hoang, 2012). The UCP system represents an 
efficacy mechanism to decrease ROS production in mitochondria (Mailloux, 
2011). The existence of a strong correlation between mitochondrial membrane 
potential and ROS production is well known (Mailloux, 2012). The uncoupling of 
oxidative phosphorylation is a short circuit in which the transport of protons from 
the intermembrane space to the matrix bypasses ATP synthase. Minor increases in 
the mitochondrial membrane potential induce ROS formation, whereas slight 
decreases can substantially diminish their production, without greatly lowering the 
efficiency of oxidative phosphorylation. Hence, the mild uncoupling of 
mitochondrial oxidative phosphorylation may represent the first line of defense 
against oxidative stress (Brand, 2005). According to this pattern, UCP2 can 
dissipate the proton gradient to prevent the proton-motive force from becoming 
excessive, thus decreasing ROS produced by electron transport (Garlid, 2000). 
Mitochondrial superoxide ion is considered the initial and leading molecule of 
ROS signaling and it is generally converted into hydrogen peroxide (H2O2) by 
superoxide dismutase. In addition, superoxide ion can generate hydroxyl radicals 
(•HO) implicated in lipid damage and protein oxidation (Cadenas, 2000).  
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Figure 11. Uncoupling protein 2 uncoupling activity in oxidative 
phosphorylation. ROS: Reactive oxygen species; UCP2: Uncoupling protein 2; SOD: 
Superoxide dismutase; Mn-SOD: Manganese-superoxide dismutase (Donadelli, 2015). 
 
Therefore, UCP2 acts as a sensor of mitochondrial oxidative stress and constitutes 
an important component of local feedback mechanisms generally implicated in 
cyto-protective activities controlling the production of mitochondrial ROS and 
regulating redox-sensitive cytosolic signaling pathways. Since UCP2 plays an 
essential role in the maintenance of cellular ROS homeostasis, it is reasonable to 
expect that it undergoes to sophisticates regulation at multiple levels, including i) 
Ucp2 gene mutation (single nucleotide polymorphisms, SNP), ii) Ucp2 mRNA 
and protein expression (transcriptional, translational, and protein turn-over 
regulation), iii) UCP2 proton conductance (ligands and post-transcriptional 
modifications), and iv) nutritional and pharmacological UCP2 regulation, as 
described in Donadelli, 2014.  One of the most important mechanisms of the 
transcriptional regulation of UCP2 is mediated by the peroxisome proliferator-
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activated receptor gamma coactivator1-alpha (PGC-1α), which has been shown to 
stimulate TR-mediated human Ucp2 gene expression via two TREs located in the 
proximal Ucp2 promoter region (figure 12) (Oberkofler, 2006). PGC-1α can also 
indirectly induce Ucp2 gene expression by co-activating liver X receptor-
mediated expression of sterol regulatory element binding protein (SREBP)-1c as 
well as dexamethasone-stimulated SREBP-2 expression. SREBP isoforms are 
known to regulate Ucp2 gene expression via either one of the two E-box motifs 
present on Ucp2 promoter (Fukuchi, 2002).  
 
 
Figure 12. Role of PGC-1α in the regulation of human UCP2 gene expression. 
Two E-Box motifs mediate the stimulatory effects of SREBP isoforms on human UCP2 
gene transcription. PGC-1α up-regulates SREBP-1c via coactivation of the LXR and 
increases SREBP-2 gene expression via coactivation of the GR, thereby indirectly 
increasing UCP2 mRNA expression. These interactions of PGC-1 with LXR and GR are 
antagonized by the transcriptional corepressor SHP. Furthermore, PGC-1α potentiates 
human UCP2 gene expression as a coactivator of the TR, which binds to two TREs in the 
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proximal UCP2 promoter region. GRE, Glucocorticoid hormone response element 
(Oberkofler, 2006). 
 
Sestrins: crucial role in antioxidant defenses 
Sestrins are encoded by genes whose expression is upregulated in cells exposed to 
a variety of environmental stresses including i) DNA damage, ii) hypoxia, iii) 
hypernutrition and chronic mTORC1 activation, iv) oxidative stress and v) 
hypoxia. Since all members of the Sestrin’s family are induced by oxidative 
stress, it is reasonable to expect their involvement in the metabolism of ROS and 
other reactive metabolites. Silencing any of Sesn1-3 by shRNA causes 
accumulation of ROS in various cell lines (Budanov, 2004), leading to DNA 
damage and chromosomal instability (Kopnin, 2007; Sablina, 2005) or cell death 
(Budanov, 2002; Nogueira, 2008 Budanov, 2004; Hagenbuchner, 2012). Sestrins 
contribute to redox homeostasis through regulation of the AMPK-mTORC1 
signaling pathway and prevent mTORC1 hyperactivation that stimulates ROS 
production through its effects on metabolism and mitochondrial function (Lee, 
2010). Sestrin-dependent activation of AMPK and suppression of mTORC1 
activity are critical for maintaining basal autophagy (Maiuri, 2009). Thus, Sestrins 
can be important for autophagic elimination of dysfunctional mitochondria that 
leak electrons and produce pathogenic amounts of ROS (Ishihara, 2013). Sestrin-
dependent inhibition of mTORC1 can be also important for autophagy-mediated 
degradation of Keap1, an inhibitor of Nrf2-dependent antioxidant gene expression 
(Bae, 2013). A recent report also demonstrated that, through AMPK activation, 
Sestrin2 can inhibit NADPH oxidase 4 (NOX4) that generates pathogenic 
amounts of cytosolic ROS (Eid, 2010; Eid, 2013). The Sestrins were also shown 
to mediate the antioxidant activities associated with the p53 and FoxO 
transcription factors (Hagenbuchner, 2012; Nogueira, 2008; Sablina, 2005). While 
high levels of oxidative stress can lead to cell death through p53- and FoxO-
dependent apoptotic gene transcription, low levels of oxidative stress cause 
moderate activation of p53 and FoxO that can induce Sestrins to reduce oxidative 
stress and prevent cell death (Lee, 2013). Sestrins are also able to directly bind to 
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AMPK, as well as to indirectly activate AMPK gene transcription stimulating 
AMPK signaling and its phosphorylation by upstream kinases, such as LKB1 
(Budanov and Karin, 2008; Chen, 2010). Despite a lot of work is still needed to 
reveal the detailed molecular functions of the Sestrins, genetic studies have clearly 
shown that Sestrins maintain metabolic homeostasis and protect cells and 
organisms from oxidative stress, mainly through the regulation of the AMPK-
TORC1 axis. 
 
3.5 AMPK: A NUTRIENT AND ENERGY SENSOR  
Many studies reported that AMPK signaling coordinates multiple metabolic 
pathways, acting as a main cellular energy sensor and a master regulator of the 
cellular metabolic homeostasis (figure 13) (Hardie, 2007).  
 
Figure 13. Effects of activation of AMPK on cellular metabolism. In the figure 
the proteins that are supposed to mediate the metabolic effects of AMPK are shown, as 
well as the final metabolic outcomes. (Hardie et al., 2012). 
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AMPK is a highly evolutionarily conserved serine/threonine protein kinase 
complex consisting of three subunits, α, β and γ. The α-subunit carries out the 
catalytic function, while β and γ subunits have a regulatory role (Hardie, 1998). 
AMPK is activated by metabolic stresses that inhibit ATP production or stimulate 
ATP consumption. Once activated, AMPK exerts its function stimulating 
catabolism and inhibiting anabolism by phosphorylating a number of downstream 
transcription factors related to metabolism and metabolic enzymes (Hardie, 2007). 
Many studies showed that activated AMPK increases PGC-1α gene expression in 
cultured muscle cells, in umbilical vein endothelial cells, in fat, and in skeletal 
muscle (Jorgensen, 2005; Terada, 2002; Girii, 2006; Terada, 2004; Suwa, 2003; 
Winder, 2006; Kuhl, 2006; Sriwijitkamol, 2006; Ojuka, 2004; Kukidome, 2006; 
Taylor, 2005). Interestingly, AMPK binds and activates PGC-1α in muscle cells 
by direct phosphorylation on two critical residues, threonine-177 and serine-538 
(Sibylle, 2007). Therefore, since PGC-1α can function as a regulator of its own 
gene expression in muscle, in a feedforward loop (Handschin, 2003) it is 
conceivable that the PGC-1α phosphorylation by AMPK is involved in the 
induction of the PGC-1α gene. Therefore, posttranslational modifications of PGC-
1α by AMPK play an important role in integrating environmental changes into the 
corresponding metabolic adjustments.  
Notably, AMPK is also a master regulator of autophagy. In fact, it inhibits 
mTORC1 through phosphorylation of TSC2 and Raptor in response to cellular 
energy cues (Gwinn, 2008; Herrero-Martin, 2009; Inoki, 2006; Matsui, 2007; 
Meley, 2006). Moreover, Kim et al. demonstrated that AMPK-dependent ULK1 
phosphorylation is a required step to trigger the autophagy machinery (Kim, 
2011). Under energetic stress, ULK1 promotes autophagy by targeting several 
downstream crucial autophagy effectors involved in the initiation of the process, 
such as the actin-associated motor protein myosin II and ATG9 [39]. Recent 
studies reported that phosphorylation of Beclin-1 by ULK1 enhances the activity 
of ATG14L-containing Vps34 complex, which is crucial for the full autophagic 
induction in mammalian cells (Russell, 2013). The functional interplay between 
AMPK and wtp53 is a well-described mechanism involved in tumor suppression. 
Indeed, the stimulation of AMPK by energy stress promotes the phosphorylation 
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and activation of wtp53 (Jones, 2005; Okoshi, 2008). Moreover, AMPK is able to 
increase both the activity and the stability of wtp53 through direct 
phosphorylation of p53 and inactivation of MDMX-mediated ubiquitination 
process, thus prolonging half-life of wtp53 itself (He, 2014). Wtp53 may in turn 
increase AMPK activity through transcriptional activation of the gene encoding 
the β subunit of the enzymatic complex (Feng, 2007) and Sestrins (Budanov, 
2008), providing a positive feedback that sustains AMPK signaling. 
 
Regulation of AMPK signaling by mutant p53 proteins  
It has been recently shown by Zhou et al. that mutp53 proteins, in contrast to their 
wild type counterpart, are able to inhibit AMPK signaling in head and neck cancer 
cells directly binding to the AMPKα subunit, thus gaining their oncogenic 
function and stimulating anabolic growth of cancer cells (Zhou, 2014). 
Interestingly, in response to glucose deprivation and metabolic stress, the 
phosphorylation on Thr172 of AMPKα, an event required for a full AMPK 
activation (Hawley, 1996), is inhibited in cancer cells expressing several GOF 
mutp53s, as R175H, P151S, G245C and R282W when compared with control 
cells lacking mutp53 expression. Moreover, Zhou et al. observed that mutp53s fail 
to regulate the expression level of the AMPK subunits excluding a transcriptional 
control in mutant p53-mediated AMPK inhibition (Zhou, 2014). After knocking-
down of endogenous mutp53 variants the authors observed an induction of both 
AMPK Thr172 phosphorylation and of its direct downstream target acetyl-CoA 
carboxylase in response to glucose deprivation or metabolic stress, providing 
further evidence that GOF mutp53s inhibit AMPK signaling. Furthermore, the 
authors demonstrated that energy stress strongly induces AMPKα-mutp53 
interaction in vivo and that mutp53s can directly interact with both AMPKα1 and 
AMPKα2 mainly through their DNA-binding domain (DBD), while the N-
terminus of mutp53s is responsible for blocking the interaction between AMPKα 
and its upstream kinase LKB1 inhibiting its Thr172 phosphorylation and 
consequently preventing its activation (Zhou, 2014). Moreover, since AMPK is a 
master energy sensor and a regulator of metabolic homeostasis, the demonstration 
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that mutp53s are actively involved in the sustaining of cell growth and regulation 
of cancer metabolism through direct inhibition of AMPK (figure 15) further 
extends the understanding of the molecular mechanisms of GOF mutp53s in 
cancers. Importantly, AMPK was recently identified as a negative regulator of the 
Warburg effect through inhibition of the hypoxia-induced factor 1 (HIF-1) 
pathway (Faubert, 2013). Therefore, the inhibition of AMPK by GOF mutp53s, 
which relieves the suppression of HIF-1 by AMPK, is expected to increase HIF-1 
protein expression and thus lead to increased glucose influx and glycolysis. This 
could represent a further mechanism of GOF mutp53 to promote the Warburg 
effect and drastic metabolic changes in cancer cells, in addition to that mentioned 
previously. The inhibition of AMPK signaling by mutp53 provides an excellent 
example of how a gene mutation in tumor cells can transform an agonistic 
relationship (i.e., wtp53 activating AMPK signaling) into an antagonistic 
relationship (i.e., mutp53 inhibiting AMPK). In this case, p53 mutation transforms 
a signaling network with tumor-suppressing functions into a network with 
oncogenic potential to promote tumor growth and progression. 
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Figura 15. GOF mutp53s with high AMPKα-binding affinity gain oncogenic 
functions to promote cell growth and cancer cell metabolism through direct inhibition of 
AMPK activation (Zhou, 2014) 
 
3.6 mTOR: A CELLULAR HUB DRIVING CELL GROWTH 
Mammalian target of rapamycin (mTOR), a serine/threonine protein kinase with a 
large molecular size, belongs to the phosphatidylinositol kinase related kinase 
(PIKK) family and it is implicated in the regulation of multiple cellular processes 
including cell growth, cell cycle, cell survival, as well as autophagy. The 
observation that treatment with rapamycin is sufficient to induce autophagy even 
in the presence of nutrients represents a valid evidence for the conclusion that 
mTOR complex is a powerful repressor of autophagy (Noda, 1998). Genetic and 
biochemical studies demonstrated that the inhibition of ULK1 by mTOR is a 
crucial mechanism by which it explicates its repressive function on autophagy 
(Chan, 2009; Mizushima, 2010). mTOR is composed by two multiprotein 
enzymatic functional complexes, mTORC1 and mTORC2 (Loewith, 2002). 
Contrarily to mTORC2, mTORC1 is sensitive to the inhibition by rapamycin and 
it is directly regulated by the cellular nutrient status, including growth factors and 
amino acids availability, playing essential roles in the regulation of protein 
translation and autophagy (figure 16). 
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Figure 16. mTORC1 signaling links cellular growth conditions with metabolic 
processes underlying anabolic cell growth and proliferation. Many physiological and 
pathological signals affect the activation status of mTORC1, including cellular nutrients 
and energy, growth factors, oncogenes and tumor suppressors, and a variety of 
intracellular pathogens. When activated, mTORC1 regulates a number of cellular 
processes, with those affecting the metabolic state of the cell emphasized in this model.. 
(Dibble and Manning, 2013). 
 
Raptor, a component of mTORC1, functions as a scaffolding protein in order to 
recruit different substrates such as p70S6 kinase-1 (S6K1) and eIF4E binding 
proteins (4EBPs) for phosphorylation by mTORC1 (Nojima, 2003; Schalm, 
2003). The ribosomal protein S6K1 is phosphorylated on Thr389 by mTORC1 
and this post-translational modification recruits phosphoinositide-dependent 
kinase-1 (PDK1) and activates many downstream targets such as eIF4B, PDCD4, 
Skar, and S6, thereby regulating mRNA processing, protein translation, and cell 
growth (Dorrello, 2006; Shahbazian, 2006). Importantly, recent studies elucidated 
the mechanism by which mTOR regulates ULK1 in autophagy blockage. Kim et 
al. unveiled that mTOR can phosphorylate ULK1 on Ser757 disrupting its 
interaction with AMPK, which is a required event to activate ULK1 and to induce 
the autophagic pathway (Kim, 2011). Therefore, mTOR complex represents a key 
factor in the cell growth process and its dysregulation, primarily due to 
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inactivating mutation in TSC1/TSC2 or constitutive activation of the PI3K 
upstream pathway, drastically contributes to tumorigenesis. Both TSC2 and 
Sestrins are key inhibitors of mTOR activity and direct targets of wtp53-directed 
transcription (Feng, 2007). TSC2 inhibits mTOR by facilitating the conversion of 
the essential mTORC1-activator Rheb-GTP to the inactive Rheb-GDP (Tee, 
2003). Sestrins have been shown to inhibit mTOR kinase activity in different 
ways, including the stimulation of AMPK activity and the suppression of mTOR 
translocation to the lysosomes (Parmigiani, 2014; Peng, 2014). Moreover, it has 
been reported that after DNA damage wtp53 exerts a negative control in the 
regulation of cancer cell growth stimulated by mTOR through the intermediate 
activation of the AMPK (Feng, 2005) 
 
PKM2 is a key multifaceted enzyme regulated by mTOR frequently enhanced in 
cancer  
Pyruvate kinase is an enzyme that catalyzes the conversion of 
phosphoenolpyruvate (PEP) and ADP to pyruvate and ATP in glycolysis and 
plays a role in regulating cell metabolism. The M2 isoform of pyruvate kinase 
(PKM2) supports anabolic metabolism and is mainly expressed in cancer tissues. 
Preferential expression of PKM2 in tumor cells is implicated in cancer cell 
survival and drug resistance, for instance, by increasing the level of the anti-
apoptotic protein Bcl-xL via enhancing NF-B p65 stabilization (Li, 2014). The 
activity of PKM2 is regulated by both intracellular pathways, including mTOR 
signaling, and metabolites. Indeed, it has been demonstrated a direct connection 
between mTOR signaling and PKM2 in cancer. (Sun, 2011). mTOR activation 
simulates HIF-1α expression, and HIF-1α in turn enhances PKM2 expression 
through the collaboration with c-Myc–hnRNPs splicing regulators (Sun, 2011). 
Subsequently, along with other glycolytic enzymes, PKM2 stimulates aerobic 
glycolysis, a metabolic shift often observed in pseudo-hypoxic tumors. The 
existence of mTOR/HIF1α/Myc–hnRNPs/PKM2 glycolysis cascade is essential 
for cell proliferation and tumor growth and the frequent hyperactivation of mTOR 
signaling during the course of the multistep oncogenesis might contribute to the 
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development of the Warburg effect in human cancers. However, the involvement 
of PKM2 in cancer is not constrained to the regulation of glycolysis. Indeed, 
beyond its dominant role in glycolysis to achieve the nutrient demands of cancer 
cell proliferation, PKM2 contributes to tumorigenesis through crucial non-
metabolic functions. It has been reported that PKM2 can translocate into the 
nucleus of the cells and directly interact with HIF-1α subunit promoting 
transactivation of HIF1-target genes by enhancing its binding and recruitment 
with the transcriptional coactivator p300 (Luo, 2011). PKM2 can further interact 
with -catenin phosphorylated by EGFR signaling and this interaction is required 
for the two proteins to be recruited to the cyclin D1 (CCND1) promoter (Yang, 
2011). Thus, PKM2-dependent -catenin transactivation is described to be 
required for EGFR-promoted tumor cell proliferation and brain tumor 
development (Wu, 2014). Intriguingly, PKM2 in addition to play a role as a 
transcriptional coactivator may function as a protein kinase that directly 
phosphorylates signal transducer and activator of transcription 3 (STAT3) 
stabilizing its nuclear localization (Gao, 2012). The activation of STAT3 in 
malignant cells is possibly one of the most important molecular signatures for 
promoting the progression of cancer (Yang, 2014). Recently, it has been described 
that the double N340Q/L344R mutant p53 promotes hepatocarcinogenesis 
through upregulation of PKM2 (Wu, 2016). Mechanistically, mutant p53 
(N340Q/L344R) forms a complex with cancer up-regulated drug resistant 
(CUDR), a novel noncoding RNA, and the complex binds and stimulates the 
promoter regions of the PKM2 gene. 
 
Regulation of mTOR signaling by mutant p53 proteins 
An increasing number of evidence highlighted that mutp53 proteins acquire the 
oncogenic ability to stimulate mTOR signaling, representing an essential turning 
point to sustain cancer cell proliferation and growth. Agarwal et al. demonstrated 
that the ectopic expression of three hot-spot p53 mutant proteins, as R175H, 
R248W and R273H, causes the hyper-phosphorylation of the mTORC1 targets 
S6K1 and 4EBP1 in both p53-null HCT116 colon carcinoma cells and H1299 
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non-small cell lung carcinoma cells, while wtp53 reduces mTORC1 activity as 
revealed by the decreased phosphorylation of S6K1 and 4EBP1 (Agarwal, 2016). 
PI3K/Akt signaling pathway plays a crucial role on tumorigenesis regulating 
relevant cellular functions including survival, proliferation and metabolism. 
PI3K/Akt pathway is generally activated by a number of growth factor receptors 
including EGFR, MET and TGFβR, which promote the phosphorylation of Akt 
that propagates the kinase cascade by phosphorylating in turn many downstream 
effectors, including its direct target mTORC1. Hyper-activation of PI3K/Akt 
signaling is often detected in many cancers and hence represents a valid 
therapeutic target currently adopted in tumor therapy (Li, 2016; Yang, 2010). 
Importantly, a number of studies demonstrated that mutp53s exert their oncogenic 
function enhancing Akt activity and this may result in a consequent 
hyperactivation of mTOR signaling with an inhibitory effect on autophagy. Tan et 
al. reported that depletion of endogenous hot-spot R273H, R280K and R280T 
mutp53 isoforms can downregulate Akt phosphorylation in MDA-MB-468, 
MDA-MB-231 and CNE-1 cancer cell lines respectively, suggesting the 
involvement of mutp53s in the promotion of Akt signaling, which leads cancer 
cell survival (Tan, 2015). Moreover, the authors showed a direct correlation 
between high expression of mutp53s and strong phospho-Akt staining in primary 
human breast cancers providing a further suggestion of the clinical relevance of 
mutp53s in the PI3K/Akt axis stimulation (Tan, 2015). Many studies 
demonstrated that mutp53s can drive tumorigenesis by activating a number of 
growth factor receptors implicated in the activation of PI3K/Akt signaling, 
including TGF-β receptor (Adorno, 2009), EGFR (Sauer, 2009; Wang, 2013), and 
MET (Grugan, 2013; Muller, 2013). Furthermore, Xu et al. reported that MDA-
MB-468, HT29 and A431 cancer cell lines expressing high levels of EGFR are 
susceptible to Akt de-phosphorylation following endogenous mutp53 depletion, 
suggesting a direct role of mutant p53 proteins in sustaining Akt pathway through 
overexpression of growth factor receptors (Xu, 2005). Accordingly, Guo et al. 
recently showed that the hot-spot R273H mutp53 enhances breast cancer cells 
migration by transcriptional downregulation of miR-30a, which can cover a role 
as tumor suppressor in non-small cell lung cancer (NSCLC) through the 
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downregulation of the Akt pathway by targeting Insulin-like Growth Factor 1 
Receptor (IGF-1R) (Guo, 2016; Wen, 2015). Functionally, the suppression of 
miR-30a by R273H mutp53 prevents the inhibitory effect of miR-30a on the IGF-
1R expression, thus leading to elevated activation of IGF-1R/Akt signaling 
cascade in tumor cells (Guo, 2016). Overall, many evidence support the 
hypothesis that the activation of PI3K/Akt and mTOR pathways by mutp53 
proteins might be a direct consequence of an oncogenic stimulation of growth 
factor receptors driven by mutp53s. 
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4. AIM OF THE STUDY 
Mutations in the TP53 gene occur in over 50% of human cancers, where most of 
them are missense mutations resulting in the expression of mutant forms of p53 
(Vousden and Lu, 2002; Waddell, 2014). In addition, p53 mutated proteins 
acquire new biological properties referred to as gain-of function (GOF) that 
contribute to the induction and maintenance of cancer (Santoro, 2014). In many 
human tumors, p53 mutations are associated with high genomic instability, poor 
prognosis, poor response to chemotherapy and accelerated tumor recurrence 
(Ganci, 2013; Liu, 2012; Walerych, 2012). Recently, we have documented that 
DNA damage induced by gemcitabine stabilized mutant p53 proteins in cell 
nuclei triggering chemoresistance and inducing the expression of cell cycle-
related genes, as Cdk1 and CCNB1, and increased cell growth (Fiorini, 2015). 
However, despite different models have been proposed to explain the GOF 
activities of mutant p53 in cancer, the detailed mechanisms remain largely 
unknown. In this thesis we would dissect novel molecular mechanisms by which 
gain of function mutant p53 proteins promote cancer cell proliferation and 
chemoresistance through the dysregulation of some signaling pathways crucial for 
metabolic homeostasis of the cells. In particular, we aimed to investigate whether 
mutant p53 oncogenic functions in cancer cells might counteract the autophagy 
pathway and alter the redox status of the cells through the aberrant regulation of 
Sestrins/AMPK axis and mTOR signaling, thus promoting cancer cell 
proliferation and chemoresistance. 
The main aims of this work can be summarized as follows: 
-To identify the phenotypic effect on autophagy and redox status of the cells 
driven by mutant p53 proteins in a panel of cancer cell lines (i.e. autophagosome 
formation, LC-3II autophagy marker, mitochondrial ROS levels); 
-To investigate the detailed molecular mechanisms underlying this regulation (i.e. 
transcriptional gene regulation and signaling pathways involved); 
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-To identify the functional role of autophagy and ROS regulation by mutant p53 
in cancer cells (i.e. stimulation of cell proliferation, chemoresistance, patient’s 
clinical outcome); 
-To propose a personalized therapy for patients carrying mutant TP53 gene, based 
on the detailed understanding of signaling pathways altered by mutp53s. 
A better understanding of the molecular basis underlying GOF mutant p53 in 
cancer are required to develop new effective personalized treatments that could 
improve the clinical outcome of cancer’s patients bearing mutant p53 proteins. 
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5. RESULTS 
 
Gain of function mutant p53 proteins inhibit the autophagic vesicles formation in 
cancer cells 
To study the functional role of GOF mutant p53 proteins in the autophagic 
mechanism, we first analyzed the endogenous level of the autophagosome vesicle 
formation by staining various cancer cell lines with the fluorescent probe MDC. 
Cancer cells with different missense mutations of the TP53 gene shoewd the 
endogenous level of the autophagosome vesicles about 5-6 folds lower than cells 
with wild-type TP53 alleles (Figure 17A). When PaCa3 and MCF7 cell lines 
(expressing the wild-type p53 protein) were knocked down for p53 expression, the 
autophagosome formation was inhibited, accordingly with the literature (Figure 
17B and C) (Crighton, 2007). Conversely, the autophagosome formation was 
significantly increased after knock-down of GOF mutant p53 in six cancer cell 
lines (Figure 17B and C). Consistent with this, overexpression of mutant p53 
(R175H or R273H) proteins in AsPC1 cells (null for p53 expression) produced a 
drastic reduction of MDC probe incorporation revealing an inhibitory role of 
mutant p53 on the autophagic process (Figure 17B and C). To further support the 
idea that mutant p53 may have a role in the inhibition of the autophagic event, we 
analyzed the expression of the autophagic receptor/adaptor SQSTM1/p62 
(sequestosome 1), whose massive accumulation is usually a consequence of 
autophagy impairment and accumulation of aggregated structures for 
ubiquitinilation (Katsuragi, 2015). Accordingly, we observed that mutant p53 
knockdown decreased p62 expression (Figure 17D). Furthermore, we evaluated 
the expression levels of the lipidated and truncated isoform II of the light chain 3 
protein (LC3-II), which is functionally involved in the formation and maturation 
of autophagic vesicles. Our findings showed that LC3-II protein expression levels 
considerably decreased in AsPC1 cells after ectopic expression of mutant R175H 
or R273H p53 proteins while increased in mutant p53-knocked down cells (Figure 
17D). We also observed that chloroquine (CQ) further increased the amount of 
LC-II in silencing mutant p53 conditions (Figure 17D), accordingly with the 
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hypothesis of the autophagic inhibitory flux together with the blockage of the 
lysosomal degradation. According to this, confocal microscopy analysis revealed 
that mutant p53 counteracts the fusion between autophagic vesicles (identified by 
LC3-GFP overexpression) and lysosomes (identified by lysotracker red probe) 
since the merged image of Panc1- shp53 cells showed a significant co-localization 
of LC3-II with lysosomes represented by yellow puncta and confirmed by the 
RGB profile (Figure 17E). Furthermore, we have examined the formation of 
autolysosomes (autophagic vesicles joined with lysosomes) using the fluorescent 
probe acridine orange (AO), which changes its fluorescence emission from green 
to red upon accumulation into lysosomal acidic compartments. The typical pH 
acidification of lysosomes during autophagic stimulation has been examined by 
AO probe staining in knocked down mutant p53 conditions (Figure 17F and G). 
Figure 17F showed that mutant p53 cell lines (Panc1 and SKBr3) had a high 
red/green fluorescence ratio in the sh-p53 condition, conversely wild-type p53 
cells (MCF7) showed a decrease of the autolysosome formation (Figure 17F). The 
microscopy experiments confirmed these results revealing the presence of red 
areas (acidic lysosomes containing accumulation of AO probe) into the cytoplasm 
of the cells interfered for mutant p53 expression (Figure 17G). Overall these data 
strongly support the statement that GOF mutant p53 proteins may contribute to 
prevent both the formation of the autophagic vesicles and their fusion with 
lysosomes in cancer cells. 
 
 
 
 
47 
 
 
 
Figure 17.  Mutant p53 counteracts autophagy. (A) The endogenous basal level of 
autophagosomes in cancer cells carrying WT or mutant p53 was analyzed using the 
incorporation of the fluorescent probe monodansylcadaverine (MDC). (B) 
Autophagosome formation assay was performed using the incorporation of MDC probe. 
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(C) Western blot of p53 using the protein extract of the samples used for (B) to test the 
effective knock down of WT or mutant p53 and the overexpression of mutant p53 in the 
various cell lines indicated. (D) Whole-cell extracts were used for Western blot analysis 
of the autophagic proteins p62/SQSTM1 and LC3 (isoforms I and II), p53 and GAPDH 
(as control loading). (E) 48 h after co-transfection with plasmids coding for LC3-GFP and 
pRSuper-p53 vector (shp53) or LC3-GFP and the empty vector (negative control; CTRL), 
Panc1 cells were fixed. Lysosomes and nuclei were stained with Lysotracker (red) and 
Hoescht (blue), respectively. The RGB profile plotted along the dashed line drawn in the 
merge image is also shown. Merge and single channel images come from a single z-
plane. Scale bar 10 mm. (F) Autolysosome formation analyzed by red/green fluorescence 
intensity ratio quantification of acridine orange (AO) staining in the indicated cells 
transfected with pRSuper-p53 vector (shp53) or with its negative control (shCTRL). (G) 
48 h after the p53 depletion Panc1 cells were stained with an AO solution and observed at 
40X magnification. Scale bar 40 µm. All the experiments presented in this figure are 
representative of three biological replicates. P-values were calculated with two-tailed t-
test. Statistical analysis: *p < 0.05 shp53 vs shCTRL; p < 0.05 R175H or R273H vs 
mock. 
 
Autophagy inhibition by mutant p53 increases the proliferation of cancer cells 
To unravel the biological role of autophagy inhibition in the aberrant proliferation 
induced by mutant p53, we knocked-down the essential autophagic protein Atg5 
in Panc1, MiaPaCa2, and MDA-MB-468 cells (Mizushima, 1998). The MDC 
assay established that Atg5 knockdown effectively repressed the autophagosome 
formation triggered by mutant p53 downregulation (Figure 18A). Importantly, the 
depletion of Atg5 caused a reversion of cell growth inhibition (Figure 18B) and a 
decrease of apoptosis (Figure 18C) stimulated by mutant p53 knockdown. These 
findings indicate that autophagy inhibition strongly contributed to the increased 
proliferation and to the concomitant down-regulation of the apoptotic stimuli 
driven by mutant p53. 
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Figure 18. Impact of autophagy inhibition by mutant p53 on cell growth and 
apoptosis. Panc1, MiaPaCa2 and MDA-MB-468 cell lines were seeded in 96-well plates 
and transfected with pRSuper-p53 vector (shp53) and/or pMSCV-Puro-miR30-Atg5 
(shAtg5), or their relative negative controls (shCTRL) for 48 h. Autophagosome 
formation (A), cell growth (B), and apoptosis (C) were determined using MDC assay, 
crystal violet colorimetric assay and annexinV/FITC binding assay, respectively. All the 
experiments presented in this Figure are representative of three biological replicates. P-
values were calculated with two-tailed t-test. Statistical analysis: * p < 0.05 shp53 vs 
shCTRL; § p < 0.05 shp53 vs shATG5 vs shp53. 
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Mutant p53 protein inhibits the expression of autophagic genes in tumoral cell 
lines 
The autophagic pathway is a complex sequence of biological events leading to 
formation, maturation and fusion of autophagosomes with lysosomes to allow the 
degradation and recycling of cellular components (Viry, 2014). These events are 
driven by a number of autophagy-related genes (ATGs), which are mostly 
transcriptionally induced by autophagic stimuli such as nutritional deprivation, 
infections or metabolic and oncogenic stress (Galluzzi, 2015). In the present 
thesis, we have shown that tumor cells carrying mutant p53 proteins escaped 
autophagic activity (Figures 17). In order to investigate the role of mutant p53 in 
autophagy inhibition, we studied whether mutant p53 proteins might control the 
expression of some crucial ATGs, as atg12, becn1, sesn1, sesn2 and dram1 genes. 
The depletion of mutant p53 by p53 siRNA smart pool oligos transfection (sip53), 
determined an increase of the mRNA expression in most of these ATGs in Panc1, 
MDA-MB-468 and SKBr3 cell lines (Figure 19A). In these cell lines, we have 
checked the CCNB1 mRNA expression as a control of our cellular systems 
(Figure 19B). Indeed, Cyclin B protein is important for the control of the cell 
cycle progression and it is a well-established mutant p53 target gene (Di 
Agostino, 2006). Conversely, the depletion of WTp53 expression in MCF7 breast 
cancer cell line led to a general decrease of the expression of ATGs (Figure 19A). 
Accordingly, ectopic expression of mutp53R175H or mutp53R273H in p53-null 
H1299 cells led to a significant reduction of ATGs transcripts (Figure 19A). 
Moreover, in Figure 19C, we reported that atg12 and becn1 transcripts increased 
substantially in three separate biological clones of MDA-MB-468 breast cancer 
cells (carrying mutp53R273H) where the mutant p53 knock-down was induced by 
doxycycline (DOX) [our elaboration of the data set from Freed- Pastor and 
colleagues published in (Freed-Pastor, 2012)]. 
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Figure 19. Autophagy-related gene regulation by mutant p53. A) The indicated 
cell lines were transfected with si-p53 and si-GFP (as control) oligonucleotides. H1299 
cells were transfected with mutp53R175H, mutp53R273H or pcDNA3 (mock) vectors for 
48 h. Gene expression analysis of the autophagy-related genes ATG12, BECN1, SESN1, 
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SESN2, and DRAM1 was performed by RT-qPCR and was normalized to GAPDH 
mRNA. *p < 0.05 si-p53 vs si-GFP and R175H or R273H vs mock. All the experiments 
are representative of three biological replicates. P values were calculated with two-tailed 
t-test. B) Indicated cell lines were transfected with pRSuper-p53 vector (shp53), with 
pCDNA-p53R175H, pCDNA-p53R273H plasmids or their negative controls (empty 
pRSuper and pCDNA3 mock vector, respectively). Gene expression analysis of CCNB1 
was performed by RT-qPCR and was normalized to GAPDH mRNA. * p<0.05 sip53 vs 
siGFP; R175H or R273H vs vector. (C) Box plot of ATG12 and BECN1 mRNAs 
expression obtained in MDA-MB-468 breast cancer cells by elaboration of data set from 
Freed-Pastor and colleagues (Freed-Pastor, 2012; Rhodes, 2004). 
 
Mutant p53 protein and autophagic genes expression in cancer patients 
In order to further investigate the inverse relationship between the expression of 
mutant p53 and two representative ATGs (atg12 and becn1 transcripts), we 
queried public gene expression data repositories (http://www.oncomine.org/) 
(Rhodes, 2004). Our analysis of the data set from Gluck et al. (Gluck, 2012) 
showed that atg12 and becn1 transcripts were significantly down-regulated in 
breast cancer patients carrying mutant p53, compared to those with WTp53 
(Figure 20A). These data strongly confirm the inhibitory role of mutant p53 in 
vitro and in vivo on the expression level of ATGs. Moreover, to test the potential 
prognostic value of ATGs in cancer patients, we considered a gene expression 
signature (atg12, becn1, sesn1, and dram1) by selecting autophagy-related genes 
that were upregulated by mutant p53 depletion in Figure 19A. To assess the 
potential correlation between the experimental autophagic gene signature and the 
patient’s clinical outcome, we focused our attention on a subgroup of breast 
cancer patients expressing mutant p53 proteins independently by intrinsic subtype 
(luminal, basal-like, Her+) (Figure 20B). We analyzed gene expression datasets 
and survival information downloaded from GEO and sorted for the presence of 
TP53 gene mutations (www.ncbi.nlm.nih.gov/geo/) (www.kmplot.com) (Gyorffy, 
2010). To analyze the prognostic value of the signature, we split patients into two 
groups (high and low expression levels of autophagic gene signature) by the 
median of the expression values. The two groups were then compared in terms of 
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relapse free survival (RFS) and distant metastasis free survival (DMFS). KM 
analysis in the Figure 20B showed that low atg12, dram1, sesn1 and becn1 
signature expression was significantly associated with a poor prognosis in the 
mutant p53 breast cancer subgroup (RFS Statistically significant results with p-
value=0.02, N=188; DMFS Statistically significant results with p-value=0.0028, 
N=83). 
 
Figure 20. (A) Box plots of ATG12 and BECN1 mRNAs expression in breast cancer 
patients (n=72 for wt-p53 and n=72 for mut-p53). Data from Gluck and colleagues were 
obtained from www.oncomine.org website (Gluck et al., 2012). (B) Kaplan-Meier 
survival curves of relapse free survival (RFS) and distant metastasis free survival 
(DMFS) of breast cancer patients bearing mutant TP53 gene classified according to the 
expression of atg12, becn1, sesn1, and dram1 signature. RFS statistically significant 
results with p-value=0.02, N=188; DMFS statistically significant results with p-
value=0.0028, N=83. The two compared groups are the patients with the highest 
expression (red) levels of the signature versus the patients with the lowest expression 
(black). 
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Mutant p53 inhibits atg12 expression by interaction with the NF-κB p50 subunit 
Mutant p53 proteins bind to the promoters of their target genes through 
cooperating with other transcription factors, such as E2F1, NF-Y, Sp1 and others 
(Di Agostino, 2006; Stambolsky, 2010; Strano, 2007; Valenti, 2015; Weisz, 
2007). Since ATG12 is an essential mediator of the initial phases of 
autophagosome vesicle formation, we studied this gene looking for consensus 
regions in the atg12 gene promoter binding potential transcriptional repressors. 
Our in silico analysis by using MatInspector software (www.genomatix.de) 
revealed the presence of two NF-κB p50 specific consensus sequences in the 
atg12 promoter: atg12 promoter Region 1 (-1055 bp) and atg12 promoter Region 
2 (-513 bp) (Figure 21A). MatInspector software uses TRANSFAC matrix that 
was able to discriminate between the specificity of binding between NF-κB p50 
and NF-κB p65 factors conferring different and specific position frequency to the 
nucleotides belonging to the promotorial consensus sequence (data not shown). 
As the NF-κB homodimer p50-p50 usually acts as a transcriptional repressor 
(Elsharkawy, 2010; Tong, 2004), we studied its recruitment onto the atg12 
promoter. Chromatin immunoprecipitation experiments (ChIP) in SKBr3 cells 
revealed that p50 was actually bound to both the two binding regions of atg12 
promoter and that this protein-DNA interaction was removed by transfection of 
siRNA p50 oligos (Figure 21B). Notably, ChIP assay showed that also mutant p53 
protein was recruited onto p50 consensus sites and its binding decreased after p50 
depletion (Figure 21B). As expected by the in silico analysis, NF-κB p65 did not 
bind the two atg12 promoter regions that recruited NF-κB p50 (Figure 21B). In 
order to support new evidence that mutant p53 and p50 bind onto the atg12 gene 
promoter, we aimed to investigate the existence of a novel floating mutp53/p50 
protein complex. Coimmunoprecipitation experiments from whole protein extracts 
of Panc1 and SKBr3 cancer cell lines endogenously expressing mutant p53 
proteins revealed the formation of a mutp53/p50 protein complex (Figure 21C). 
Again, NF-κB p65 isoform was not detected in this protein complex in any 
coimmunoprecipitation conditions, confirming its absence on the regions of the 
atg12 promoter as previously discussed (Figure 21C). We supported this result by 
also showing the formation of the complex between the overexpressed 
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mutp53R175H and endogenous p50 proteins in H1299 cells (Figure 21C). 
Strikingly, the depletion of p50 led to the resumption of atg12 mRNA 
transcription in mutant p53 Panc1 and MDA-MB-468 cells (Figure 21D). 
According to the above results, the p50 knock down had a functional effect on the 
increase of autophagosome formation only in SKBr3 and Panc1 cells (bearing 
mutant p53), thus supporting the inhibitory role of mutant p53/p50 complex in the 
autophagic process (Figure 21E). 
 
56 
 
Figure 21. Mutant p53 inhibits atg12 expression by interaction with NF-κB p50 
subunit. (A) Schematic representation of the atg12 promoter regions containing NF-κB 
p50 consensus box sequences analyzed in ChIP assays. Atg12 promoter: two regions at 
1055 bp (region 1) and 513 bp (region 2) upstream the first exon of ATG12 gene. The 
TSS is indicated and it was predicted by Eponine software (Down and Hubbard, 2002). 
(B) Cross-linked chromatin derived from sip50-treated SKBr3 cells and from siGFP-
transfected control, was immunoprecipitated with the indicated antibodies or in the 
absence of antibody, and analyzed by RT-qPCR with specific primers (see Material and 
Methods) for the indicated regions in the Figure 4A. The P-values were calculated with 
two-tailed t-test. * p < 0.05. (C) (Left panel). Immunoprecipitations of NF-κB p50 or NF-
κB p65 proteins and western blot analysis for p53 binding are performed from lysates of 
the indicated cancer cell lines expressing mutant p53 proteins (described in Material and 
Methods). NF-κB p50 or NF-κB p65 proteins were immunoprecipitated with their relative 
rabbit polyclonal antibody and the same amount of rabbit IgG was used as negative 
control of IP. (Right panel) Cell lysate from H1299 cells over-expressing mutp53R175H 
protein was immunoprecipitated with p53 sheep polyclonal antibody. Cells transfected 
with the empty vector (pcDNA3) was used as negative control. (D) Cells were transfected 
with the siRNAp50 or its negative control for 48 h. Gene expression analysis of ATG12 
mRNA was performed by RT-qPCR and normalized to GAPDH mRNA. The P-values 
were calculated with two-tailed t-test. Statistically significant results were with p-value < 
0.05. (E) Cells were transfected with siRNAp50 or its relative negative control. 
Autophagosome formation assay was performed using the incorporation of MDC probe. 
Statistical analysis: * p<0.05 p53 or p50 vs No Ab; § sip50 vs CTRL. 
 
Mutant p53 proteins inhibit AMPK and stimulate mTOR signaling  
In order to examine whether mutant p53 impinged in the crucial regulatory kinase 
complexes of the autophagic process we analyzed the protein expression and the 
phosphorylation state in different cancer cell lines expressing wild type or mutant 
p53 proteins. We found that the knock down of mutant p53 in either Panc1 and 
SKBr3 cell lines led to an increase of Sestrin1 and Sestrin2 protein levels, while 
silencing of wild type p53 in PaCa3 and MCF7 cancer cells resulted in a general 
down-regulation of Sestrin protein levels (Figure 22A). Sestrins are a class of 
proteins that can directly interact with AMPK subunits favouring their 
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phosphorylation by upstream kinases and thereby resulting in AMPK signaling 
stimulation (Budanov and Karin, 2008; Morrison, 2015; Sanli, 2012). To 
determine whether mutant p53 could affect the phosphorylation of AMPK, we 
analyzed the level of phospho-AMPKα (Thr172) after modulation of mutant or 
wild type p53 expression. We observed that depletion of mutant p53 was able to 
increase the phosphorylation level of AMPK [P(Thr172)-AMPK/AMPK] and to 
decrease that of p70S6K [P(Thr)389- p70S6K/p70S6K], a direct target of mTOR 
signaling (Figure 22A). Accordingly, the ectopic expression of mutp53R175H or 
mutp53R273H clearly determined the repression of AMPK phosphorylation and 
the increase of p70S6K phosphorylation (Figure 22A). To better represent our 
results, we quantified P-AMPK/P-p70S6K ratio (Figure 22B), highlighting that 
wild type and mutant p53 proteins produced inverse effects on these signaling 
pathways. 
 
 
Figure 22. Mutant p53 inhibits AMPK and stimulates mTOR. (A) Western 
blotting analysis was performed with 50 μg of whole cell extracts and probed with the 
indicated antibodies. This analysis was representative of three biological replicates. (B) 
Quantitative analysis of P-AMPK/P-p70S6K ratio. 
 
To address the role of mutant p53-dependent AMPK de-phosphorylation, we 
inhibited AMPK activity treating cancer cells with compound C (CC) or 
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overexpressing a dominant negative (DN) AMPK isoform in mutant p53 knock-
down conditions (shp53) (Figures 23A and 23B). Strikingly, AMPK signaling 
inhibition by both CC and DN-AMPK strongly rescued the autophagosome 
formation induced by mutant p53 knockdown (Figure 23A). Consistently, in the 
same conditions of AMPK signaling inhibition the oncogenic proliferation 
impaired by mutant p53 knock down was restored in all cell lines tested (Figure 
23B). Overall, these results provide robust evidence that mutant p53 exerts its 
inhibitory activity on the autophagy throughout the constitutive blockage of the 
AMPK signaling. 
 
Figure 23. The indicated cell lines were transfected for 48 h with the pRSuper-p53 
vector (shp53) or its negative control (shCTRL), in the absence or presence of 20 μM 
Compound C (CC) or together the expression vector coding for WT or dominant negative 
(DN; mutant R531G) AMPK γ2 subunit. Autophagosome formation (A) and cell growth 
(B) were analyzed by using MDC and crystal violet staining, respectively. Statistical 
analysis: * p<0.05 shp53 vs CTRL;  R175H or R273H vs mock; § p<0.05 shp53+CC vs 
shp53; # p<0.05 shp53+DN-AMPK vs shp53+WT-AMPK 
 
Mutant p53 inhibits Beclin1 phosphorylation by mTOR and its expression level 
Since mTOR pathway was triggered by mutant p53 (Figure 22), we hypothesized 
that mTOR complex induced by mutp53 might de-phosphorylate Beclin1 via 
ULK1 inhibition impairing the formation of Beclin1-mediated autophagic protein 
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complexes and autophagy maturation (Russell, 2013). To gain insight into the 
molecular mechanisms controlling the Beclin1 expression, we observed that the 
overexpression of mutp53R175H or mutp53R273H proteins in AsPC1 cells 
decreased both Beclin1 phosphorylation in Serine 15 and its total protein 
expression level (Figure 24A). Accordingly, the depletion of mutant p53 from 
Panc1 cells exerted the inverse results (Figure 24A). These data correlated with 
the Beclin1 mRNA expression shown in Figure 19. In line with the findings from 
Russel and colleagues, we also investigated whether the stimulation of mTOR 
signaling by mutant p53 may be responsible for the decrease of Beclin1 
phosphorylation. We observed that the addition of everolimus (RAD001), an 
inhibitor of mTOR currently used in the therapy against several human cancers, 
was able to completely restore Beclin1 phosphorylation repressed by the 
overexpression of both R175H or R273H mutant p53 proteins, indicating that 
mTOR stimulation by mutant p53 is highly involved in Beclin1 de-
phosphorylation (Figure 24A). Since Beclin1 phosphorylation has been described 
to be crucial for ATGs interaction during autophagosome vesicles formation, we 
investigated the role of Beclin1 repression on overall autophagy inhibition by 
mutant p53. We observed that the knockdown of Beclin1 (siBeclin1) significantly 
reduced the autophagosome formation induced by the depletion of mutant p53 
protein (Figure 24B), thus suggesting a role for Beclin1 repression on the 
autophagy pathway inhibition driven by mutant p53. According to this, the 
concomitant depletion of mutant p53 and Beclin1 led to a partial rescue of 
proliferation ability of cancer cells as compared to mutant p53 knockdown 
conditions (Figure 24C). Overall, our data strongly support the negative effect of 
mutant p53 on the Beclin1 functionality throughout the inhibition of both its 
expression and phosphorylation via mTOR stimulation.  
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Figure 24. Mutant p53 inhibits Beclin1. (A) AsPC1 cells were transfected for 48 h 
with the plasmids coding for mutant p53 proteins (R175H or R273H), or with pCDNA3 
as negative control (mock), in the absence or presence of 5 μM everolimus (EVE). Panc1 
cells were knocked-down for mutant p53 expression by 48 h of pRSuper p53 vector 
transfection (shp53). Whole-cell extracts were used for Western blot analysis using the 
indicated antibodies. (B and C) Panc1 and SkBr3 cells transfected with the pRSuper-p53 
vector (shp53) and/or si-Beclin1 oligos (siBeclin1). Autophagosome formation (B) and 
cell growth (C) were analyzed after 48 h after transfection by using MDC and crystal 
violet staining, respectively. The P-values were calculated with two-tailed t-test. 
Statistical analysis: § p<0.05 shp53+siBeclin1 vs shp53. 
 
 
 
Mutant p53 regulates mTOR-dependent PKM2 and STAT3 expression 
Mutant p53 has been previously described to stimulate the aerobic glycolysis 
pathway in cancer cells (i.e. Warburg effect) (Zangh, 2013) and mTOR kinase 
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complex regulation is known to be strictly linked with metabolism regulation. 
Data presented so far indicate that mutant p53 plays an important role in the 
modulation of mTOR pathway to repress the autophagy biological process. 
Consistent with this concept, our next question was to know whether mutant 
p53/mTOR axis was able to interconnect with other metabolic pathways 
functionally linked to autophagy. We investigated whether the expression levels 
of pyruvate kinase type M2 (PKM2), an isoform of pyruvate kinase commonly 
over-expressed in tumors (Yang, 2013) can be influenced by mutant p53. 
Pyruvate kinase (PK) is a rate-limiting enzyme in the final step of the glycolytic 
pathway that catalyzes the conversion from phosphoenolpyruvate and ADP to 
pyruvate and ATP. Notably, we observed that mutant p53 knockdown inhibited 
both PKM2 and P(Tyr105)-PKM2 expression levels while they resulted 
unchanged after WTp53 knockdown (figure 25A). To investigate the involvement 
of mTOR kinase complex in PKM2 regulation, we have over-expressed R175H or 
R273H p53 mutants in p53-null AsPC1 cells in the absence or presence of the 
mTOR inhibitor everolimus. Figure 25B shows that mutant p53 proteins 
significantly increased both P-PKM2 and PKM2 expression. Furthermore, PKM2 
phosphorylation was rescued after the incubation with everolimus, thus 
demonstrating the crucial role of mTOR on PKM2 regulation by mutant p53. 
Intriguingly, beyond its metabolic roles, PKM2 can trigger the expression of 
genes related to cancer cell migration, such as the signal transducer and activator 
of transcription 3 (STAT3) (Yang, 2014). On turn, STAT3 has been also 
described to sustain aerobic glycolysis and the Warburg effect in cancer cells (Li, 
2015), as well as to inhibit autophagy by down-regulating LC3 gene expression 
(Gong, 2014). In this context, we found that mutant p53 proteins up-regulated 
both STAT3 and P(Tyr705)-STAT3 expression levels in a mTOR-dependent 
manner (figure 25B). 
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Figure 25. Mutant p53 regulates PKM2 and STAT3 by mTOR pathway.  (A) 
Cells were transfected for 48 h with pRSuper-p53 vector or with the empty vector as 
negative control (CTRL). Whole-cell extracts were used for Western blot analysis using 
the indicated antibodies. (B) Cells were transfected for 48 h with the plasmids coding for 
mutant p53 proteins (R175H or R273H), or with empty pCDNA3 as negative control 
(CTRL), in the absence or presence of 5 μM everolimus. Whole-cell extracts were used 
for Western blot analysis using the indicated antibodies. 
 
 
Mutant p53 sensitizes cancer cells to mTOR inhibition  
Everolimus is an inhibitor of mammalian target of rapamycin (mTOR) routinely 
used in the targeted therapy of many cancers. We aimed to investigate whether 
cancer cells bearing mutant p53 might be more responsive to everolimus than wild 
type p53 cancer cells, accordingly with the inhibitory role of mutant p53 on 
autophagy via mTOR pathway induction (Figures 24 and 25). To demonstrate this 
idea, we incubated Panc1, SkBr3 and MCF7 cell lines with everolimus and 
observed that the cells expressing mutant p53 (Panc1 and SKBr3) were more 
sensitive than cells with wild type p53 (MCF7) to the treatment as reported by the 
IC25 and IC50 values (Figure 26A). To functionally demonstrate the involvement 
of mutant p53 on cancer cell sensitivity to everolimus, we evaluated the response 
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of the cells after knockdown or overexpression of p53 mutant proteins. Our data 
reported in Figure 26B, showed that mutant p53 knockdown significantly 
decreased Panc1 and SkBr3 cell response to everolimus treatment if compared to 
controls. To corroborate this result, we assessed that the overexpression of R175H 
or R273H mutant p53 conferred to p53-null AsPC1 cells a strong sensitization to 
everolimus incubation, as compared to its negative control (mock vector). 
Moreover, the dominant negative effect of mutant p53 proteins ectopically 
expressed in WTp53 cells (PaCa3), allowed a stronger impact resulting in a higher 
response to everolimus incubation in comparison to PaCa3 cells under control 
conditions (Figure 26B). Overall, these results demonstrated that targeting the 
mTOR pathway represents an effective therapeutic strategy for cancer patients 
bearing mutations in the TP53 gene. 
 
 
 
Figure 26. Mutant p53 sensitizes cancer cells to everolimus. (A) Cells were 
treated for 48 h with increasing concentrations of everolimus. Cell growth was measured 
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using the crystal violet colorimetric assay and IC25 and IC50 values for each cell line 
tested have been reported. (B) Cells were transfected with pRSuper-p53 vector (shp53) 
and with the plasmids coding for mutant p53 proteins (R175H or R273H), or with empty 
pRSuper (shCTRL) or pCDNA3 (mock), respectively, as negative controls. For each 
experimental condition, cells were untreated or treated with 5 μM everolimus for 48 h. 
Cell growth was determined using the crystal violet colorimetric assay. The rate of cell 
growth inhibition corresponds to the effect of everolimus, as compared to vehicle 
(untreated), in each indicated transfection condition. The P-values were calculated with 
two-tailed t-test. Statistical analysis: * p<0.05 shp53 vs shCTRL; § p<0.05 R175H or 
R273H vs mock. 
 
 
Mutant p53 proteins enhance ROS production in cancer cells 
In order to investigate the effect of mutant p53 on the redox balance of cancer cell 
we have transiently transfected pancreatic and breast cancer cell lines with 
pRSuper-p53 vector and subsequently measured the cytosolic ROS level by using 
the dichlorodihydrofluorescein (DCF) probe. We found that the knock-down of 
mutant p53 in Panc1 pancreas cancer cells and MDA-MB-468 breast cancer cells 
(both carrying mutp53R273H), or in SKBr3 breast cancer cells (bearing 
mutp53R175H), led to a decrease of cytosolic ROS levels (figure 27A and C). In 
contrast, silencing of wild-type p53 in PaCa3 pancreas cancer cells and MCF7 
breast cancer cells resulted in an increased oxidative stress, according with the 
antioxidant effect of p53 (figure 27A and C). GSH serves numerous important 
functions, including antioxidant defense, storage of cysteine, maintenance of 
intracellular redox state, and modulation of cell growth (DeLeve, 1991). 
Therefore, in order to further investigate the effect of mutant p53 on the oxidative 
status of cancer cells we have determined the intracellular reduced glutathione 
(GHS) levels (in nanomole-per-milligram protein). We observed that the transient 
silencing of R273H-mutp53 leads a significant decrease in the intracellular GSH. 
In contrast, silencing of its wild-type p53 counterpart leads an increase of GSH 
(figure 27B). These observations were in accordance with the ability of mutant 
p53 to induce ROS. 
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Figure 27. Mutant p53 proteins enhance ROS production in cancer cells. (A) 
DCF fluorescence intensity, corresponding to ROS production level, measured by a 
multimode plate reader. The cells line indicate were seeded in 96-well plates, incubated 
overnight, and transfected with the pRSuper-p53 vector and with plasmids for the ectopic 
expression of mutant p53 (o.e. R175H; o.e. R273H), or their relative negative control 
(CTRL) (A). (B) The intracellular oxidized and reduced glutathione were determined in 
MCF7 and Panc1 cell lines after transient transfection with the pRsuper-p53 vector. Data 
are presented as means ± SD of results from four independent experiments. Significant 
difference compared to control group (*p≤0.05). (C) Western blot of p53 using the 
protein extract of the samples used for (A and B) to test the effective knock down of WT 
or mutant p53 and the overexpression of mutant p53 in the various cell lines indicated. 
In order to collaborate our previous results and investigate the effect of mutant 
p53 on mitochondrial ROS we performed a confocal microscopy analysis on 
AsPC1 pancreas cancer cell line which revealed that ectopic expression of mutant 
p53 (R175H and 273H) is able to strongly induce mitochondrial superoxide ion 
production (identified by MitoSox red probe), in contrast to cells transfected with 
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empty vector (figure 28A). We also demonstrated a significant co-localization 
between mitochondrial superoxide ions and mitochondria (identified by 
Mitotracker green probe) as shown in the merged images of AsPC1 cells that 
ectopically over-express both R175H and R273H mutant p53 by yellow puncta 
and confirmed by the RGB profile (figure 28A). The quantification of superoxide 
production using MitoSox Red probe was determined with a multimode plate 
reader and is reported in figure 28B. Overall, our results strongly support that 
mutant p53 isoforms were able to strongly induce mitochondrial superoxide 
production, thus affecting redox balance in cancer cells. 
 
 
Figure 28. Mutant p53 proteins enhance mitochondrial ROS production. A) 48 h 
after transfection with either plasmids coding for R175H and R273H mutant p53 vector 
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and the empty vector (negative control; CTRL), cells were incubated with MitoSox probe 
(red) for 1h and subsequently fixed. Mitochondria and nuclei were stained with 
Mitotracker (green) and Hoescht (blue), respectively. The RGB profile plotted along the 
dashed line drawn in the merge image is also shown. Merge and single channel images 
come from a single z-plane. Scale bar 10 μm. (B) Mitochondrial superoxide production 
determined with the MitoSox Red probe measured by a multimode plate reader. Cells 
were seeded in 96-well plates, incubated overnight, and treated with 100 μg/ml ONC for 
72 h. 
 
ROS induced by mutant p53 proteins are critical to mediate their oncogenic 
proprieties 
We have previously established that mutant p53 has a crucial effect in the 
dysregulation of the redox balance in cancer cells by enhancing ROS production. 
It has been described that ROS can act as second messengers in cellular signaling 
(Finkel, 2011) and a great amount of studies has deeply unveiled the existence of 
a ROS-mediated regulation in many cellular pathways (reviewed in Liu and Storz, 
2010). Moreover, as we have previously described, oxidative stress-mediated 
signaling events play exceptional relevance in the development and progression of 
many human cancer, since have been reported to affect all characters of cancer 
cell behavior (Fiaschi and Chiarugi, 2012). Since the existence of these evidences, 
we moved to investigate the functional role of the ROS induced by mutant p53. 
Herein, we demonstrated that the increase of cancer cell proliferation induced by 
ectopic expression of both R175H and R273H p53 isoforms in AsPC1 p53-null 
cells was abolished when they were concomitantly treated with the antioxidant 
compound N-Acetyl-Cysteine (NAC) (figure 29A). Moreover, we observed that 
the reduction of apoptosis due to ectopic expression of both R175H and R273H in 
AsPC1 cells was rescued when the cells were treated with NAC (figure 29B), 
corroborating our hypothesis by which ROS might play as signaling molecules 
modulating specific pathways resulting in an inhibitory effect on apoptosis. We 
have previously described that mutant p53 drive chemoresistance in pancreatic 
cancer cells following gemcitabine treatment (GEM) (Fiorini et al., 2015). 
Intriguingly, we showed herein that ROS also are keys mediators of the 
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chemoresistance induced by mutant p53 proteins play a role in the 
chemoresistance induced by mutant p53. Confirming our previous data, AsPC1 
p53-null pancreas cancer cells treated with GEM gained a significant 
chemoresistance when transfected with R175H and R273H p53 proteins, and this 
chemoresistance were drastically abolished when the cells were concomitantly 
treated with NAC (figure 29C) suggesting a key role of ROS in the induction of 
chemoresistance induced by mutant p53. Overall, these intriguing results confirm 
that ROS are critical mediators of the GOF mutant p53 in cancer cells. 
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Figure 29. ROS induced by mutant p53 proteins are critical to mediate their 
oncogenic proprieties. (A) AsPC1 p53 null cells were transfected with R175H and 
R273H vector, or negative control, and concomitantly treated with NAC at 7 mM for 24h. 
Cell proliferation was measured by Cristal Violet assay, as described in material and 
methods. (B) AsPC1 p53 null cells were transfected with R175H and R273H vector, or 
negative control, and concomitantly treated with NAC at 7 mM for 24h. Apoptosis was 
determined by annexinV/FITC binding assay. Statistical analysis: *CTRL vs R175H and 
R273H. *p<0.05. # R175H and R273H vs R175H + NAC and R273H + NAC. #p<0.05 
P-values were calculated with two-tailed t-test. (C) AsPC1 p53 null cells were transfected 
with R175H and R273H vector, or negative control, and concomitantly treated with GEM 
at 1uM and NAC at 7 mM for 24h. Cell proliferation was measured by Cristal Violet 
assay. Statistical analysis: *p<0.05 
 
Mutant p53 downregulates UCP2 and PGC1-α 
PGC-1α is a multiple-function transcription coactivator that regulates the activity 
of multiple nuclear receptors and transcription factors involved in the 
mitochondrial biogenesis and in the maintaining of ROS homeostasis (reviewed 
in: Puigserver, 2003). We have reported above that its activity is linked to AMPK 
since it can phosphorylate PGC1-α sustaining a feedforward loop that increases its 
gene transcription (Lin, 2005). UCP2 plays a crucial role in the limiting 
mitochondrial ROS that are generated by electron leakage form oxidative 
phosphorylation (Garlid, 2000) and its expression is intimately linked to the 
activity of PGC-1α (Oberkofler, 2004). In pancreatic beta-cells, PGC-1α has been 
shown to stimulate human UCP2 gene expression via two TREs located in the 
proximal UCP2 promoter region (Oberkofler, 2006). Therefore, PGC-1α/UCP2 
axis is a relevant player in the maintenance of a correct redox balance in the cells. 
Since we have previously reported that mutant p53 was able to downregulate 
SESN1 and SESN2 (figure 19) and this resulted in an inhibition of AMPK 
phosphorylation (figure 22), we moved to investigate whether this could have any 
implication in the regulation of UCP2 and PGC-1α expression, which are two 
downstream effectors of SESN/AMPK signaling pathway. Herein, we show that 
the depletion of R273H mutant p53 determined an induction of both PGC-1α and 
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UCP2 mRNA levels in Panc-1 pancreas cancer cells (figure 30A), consistently 
with its inhibitory activity on PGC-1α/UCP2 axis. In contrast, silencing of wild-
type p53 doesn’t have a significant effect on their expression (figure 30B). 
Accordingly, ectopic expression of mutp53R273H in p53-null AsPC1 cells led to 
a significant reduction of PGC-1α and UCP2 transcripts (figure 30C). To further 
investigate the effect of mutant p53 on UCP2 protein expression we performed 
western blot experiments in p53-null AsPC1 after over-expression of 
mutp53R175H and mutp53R273H that confirmed a significant reduction of UCP2 
protein (figure 30 D). Therefore, our data strongly suggest that mutant p53 is able 
to inhibit PGC-1α and UCP2 expression. 
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Figure 30. (A-B) The indicated cell lines were transfected for 48 h with the pRSuper-
p53 vector or its relative negative control (CTRL). Gene expression analysis of the p53, 
UCP2 and PGC-1α was performed by RT-qPCR and was normalized to GAPDH mRNA. * 
p<0.05. C) Gene expression analysis of the UCP2 and PGC-1α was performed by RT-qPCR 
and was normalized to GAPDH mRNA. * p<0.05. (D) Western blotting analysis was 
performed with 50 μg of whole cell extracts, probed with the indicated antibodies and 
quantified with ImageJ. All the experiments are representative of three biological replicates. 
 
Inhibition of PGC-1α/UCP2 axis by mutant p53 leads an enhancement of ROS 
production in cancer cells 
Since we have reported that UCP2 inhibition by mutant p53 plays a critical role in 
regulation of oxidative status in cancer cells (figure 31), we moved to investigate 
the mechanisms underlying the regulation of PGC-1α/UCP2 axis mediated by 
mutant p53. Herein, we reported that the inhibition of UCP2 and PGC-1α 
transcripts obtained after ectopical expression of R273H mutant p53 in AsPC1-
p53 null cells was completely abolished when the cells were concomitantly 
treated with 5-aminoimidazole-4-carboxamide ribonucleotide (AICA-R), a 
stimulator of AMPK activity (figure 31A). As positive control, we observed that 
the AICA-R treatment induced UCP2 and PGC-1α more than double, in according 
with the previous observation by Jager et al., 2007. Moreover, we demonstrated 
that the inhibition of AMPK activity, after transient expression of its dominant 
negative (DN) isoform, was able to rescue the induction of both PGC1α and 
UCP2 consequent to knock-down of mutant p53 in Panc1 cancer cells (Figure 
31B). In order to corroborate the existence of a PGC-1α/UCP2 axis regulated by 
mutant p53 we showed that the silencing of PGC-1α was able to strongly rescue 
the induction of UCP2 consequent to knock-down of mutant p53 in Panc1 cancer 
cells (Figure  31C). These evidence reinforce our model, which indicates that 
mutant p53 proteins act as a negative upstream regulator of AMPK-
phosphorylation inhibiting PGC-1α/UCP2 expression with relevant impact on 
cellular ROS homeostasis.  
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Figure 31. (A) AsPC1-p53 null cells were transfected with the vectors for p53-
R273H expression and its mock control and treated with 1 mM AICA-R for 48h. Gene 
expression analysis of the UCP2 and PGC-1α was performed by RT-qPCR and 
normalized to GAPDH mRNA. # mock vs mock + AICA-R # p<0.05. * mock vs R273H 
and R273H vs R27H + AICA-R. * p<0.05. (B-C) Panc1 cells were transfected for 48h 
with the indicated vectors and their relative negative controls. Gene expression analysis 
73 
 
of UCP2 and PGC-1α was performed by RT-qPCR and was normalized to GAPDH 
mRNA. * and # p<0.05. P-values were calculated with two-tailed t-test. 
 
Furthermore, we have shown that the regulation of ROS levels by mutant p53 is 
AMPK-mediated and that the inactivation obtained with the expression of AMPK-
dominant negative (DN) isoform largely abolishes the decrease of ROS that we 
observed after knock-down of mutant p53 (figure 32A). Intriguingly, we have also 
observed that the reduction of intracellular ROS levels after silencing of mutant 
p53 was completely rescued when the cells were co-transfected with specific 
siRNA against UCP2 and concomitantly with pRSuperp53 in order to have a dual 
knock-down of both UCP2 and mutant p53 (figure 32B). This result reinforces the 
statement that mutant p53 induces ROS production through the inhibition of 
UCP2. A similar effect was obtained when UCP2 was inactivated by genipin 
treatment, a specific inhibitor of UCP2 activity (figure 32B). Moreover, AsPC1 
p53-null cells were transfected with the vector for ectopic mutant p53 R175H or 
R273H expression and concomitantly with a vector for UCP2 over-expression. In 
these conditions, we observed that the increase of ROS levels due to ectopic 
expression of p53 mutant was restrained when the cells were co-transfected with 
the UCP2 vector (figure 32B). Finally, we reported that the enhancement of 
mitochondrial superoxide ion production due to ectopic expression of R175H or 
R273H mutant p53 in AsPC1 p53-null cells was significantly rescued by the 
concomitant transfection with the UCP2 (figure 32C). The results strongly suggest 
that the inhibitory role that mutant p53 exerts on UCP2 expression represents a 
key mechanism to alter the oxidative status in cancer cells by enhancing 
mitochondrial ROS. 
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Figure 32. (A) The indicated cells were transfected with the pRSuper-p53 vector or 
its negative control. DCF fluorescence intensity, corresponding to overall ROS levels was 
measured by a multimode plate reader. *CTRL vs sh-p53; *p<0.05. # sh-p53 vs sh-p53 + 
DN-AMPK; #p<0.05. P-values were calculated with two-tailed t-test. (B) Panc1 
mutR273H p53 and AsPC1 p53 null cells were transfected with pRSuperp53 and vector 
for mutant p53 ectopic expression respectively and their controls. In addition, these cell 
lines were co-transfected with siRNA against UCP2, and treated with genipin for 24h. 
DCF fluorescence intensity, corresponding to ROS production level, was measured by a 
multimode plate reader. *CTRL vs sh-p53 or CTRL vs R175H or R273H; *p<0.05. #sh-
p53 vs sh-p53 + si-UCP2 or genipin.  #R175H and R273H vs R175H + UCP2 and R273H 
+ UCP2; #p<0.05. P-values were calculated with two-tailed t-test. (C) AsPC1-p53 null 
cells were transfected with the vectors for mutant p53 expression and its mock control. 
Mitochondrial superoxide production was determined with the MitoSox Red probe 
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measured by a multimode plate reader. *CTRL vs R175H or R273H; *p<0.05. #R175H 
and R273H vs R175H + UCP2 and R273H + UCP2; #p<0.05. P-values were calculated 
with two-tailed t-test. 
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6. MATERIALS AND METHODS 
Chemicals 
Chloroquine diphosphate (CQ), 3-methyladenine (3MA), N-acetyl-L-cysteine 
(NAC) and everolimus (EVE; RAD-001) were obtained from Sigma (Milan, 
Italy). Compound C (CC) solution was obtained from Calbiochem (Merck; 
Darmstadt, Germany). 
 
Cell culture 
PaCa3 (WTp53), Panc1 (mutant p53-R273H), PaCa44 (mutant p53-C176S), 
MiaPaCa2 (mutant p53-R248W), Suit-2 (mutant p53-R273H) and AsPC1 (p53-
null) human pancreatic adenocarcinoma cell lines were grown in RPMI medium 
(Life Technologies, Milan, Italy), while lung cancer H1299 (p53-null), breast 
cancer MCF7 (WTp53), SKBr3 (mutant p53-R175H), MDA-MB-468 (mutant 
p53-R273H) and MDA-MB-231 (mutant p53-R280K) cell lines were cultured in 
DMEM medium (Life Technologies, Milan, Italy). Both culture media were 
supplemented with 10% FBS, and 50 μg/ml gentamicin sulfate (BioWhittaker, 
Lonza, Bergamo, Italy). Cell lines were incubated at 37°C with 5% CO2. The list 
of the cell lines used in this study and their p53 status are summarized in Table 1. 
 
Tab. 1 Tissue of origin and p53 status of cancer cell lines 
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Cell proliferation assay 
Cells were seeded in 96-well plates (5 × 10
3
 cells/well) and the day after were 
incubated with various compounds at the indicated conditions or transfected with 
the indicated constructs (see figure legends). At the end of the treatments, cell 
growth was measured by Crystal Violet assay (Sigma, Milan, Italy) according to 
the manufacturer's protocol, and absorbance was measured by spectrophotometric 
analysis (A595nm).  
 
Transient transfection assays 
Exponentially growing cells were seeded at 5 × 10
3
 cells/well in 96-well plates or 
at 2.5 × 10
5
 cells in 60 mm cell culture plates. The ectopic expression of mutant 
p53 in p53-null cancer cells was carried out transfecting pcDNA3-mutp53R273H 
or pcDNA3-mutp53R175H expression vectors, or their relative negative control 
(pcDNA3). The ectopic expression of wild type or dominant negative (DN)-
AMPK subunit γ2 was obtained by transfection of the pcDNA5/FRT expression 
vector containing the human wild type AMPK γ2 subunit or the mutated R531G 
protein which were kindly provided by Dr. Hawley (University of Dundee, 
Scotland, UK). The ectopic expression of UCP2 was obtained with a pCMV 
expression vector containing the human cDNA of UCP2 (OriGene Technologies, 
Rockville, MD) using Lipofectamine 2000 (Life Technologies), according to the 
manufacturer's instructions. Cells transfected with the empty vector were used as a 
negative control. Wild-type and mutant p53 protein expression was transiently 
knocked-down by transfection with pRSUPER-p53 or pLVTHM-p53 vectors or 
their negative controls (pRSUPER or pLVTHM), kindly provided by Dr. Agami 
(The Netherlands Cancer Institute, Amsterdam) (Brummelkamp et al., 2002) and 
by Dr. Sergio Ruiz (CNIO, Madrid, Spain), respectively. Commercial siRNA 
smart pool of three oligonucleotides  (sip53) transiently targeting p53 (Santa Cruz 
Biotech. sc-29435) was used in the experiments of RT-qPCR to exclude back-side 
effects and to confirm the robustness of the data. A si-GFP as non-silencing 
control 5'-GGCTACGTCCAGGAGCGCACC-3' was used as a negative control. 
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The silencing transfections were carried out for 48 hrs using Lipofectamine 2000 
(Life Technologies), according to the manufacturer's instructions. Knockdown of 
Atg5 expression was performed by shRNA-Atg5 cloned in pMSCV-Puro-miR30 
vector (or its negative empty vector) kindly provided by Dr. Hans-Uwe Simon 
(University of Bern, Switzerland) (Maskey, 2013). Knock-down of Beclin1 
expression was obtained by transfecting cells with specific Beclin1 small 
interfering (si) RNA having the following sequences: 5′-
ACAGUGAAUUUAAACGACAGCAGCU-3′ and 5′- 
AGCUGCUGUCGUUUAAAUUCACUGU-3′ and with a siRNA-CTRL 
(negative control): 5′- CAGUCGCGUUUGCGACUGG-3′ purchased from Life 
Technologies. Knock-down of p50 NF-κB subunit expression was obtained by 
transfecting cells with a specific 21-nt-long interfering RNA duplex with two 3’-
end overhang dT nucleotides. The sequence of the antisense strand of the anti p50 
siRNA was 5’-AGUCCAGGAUUAUAGCCCCdTdT-3’ (MWG Biotec, 
Ebersberg, Germany; or Dharmacon, Lafayette, CO) as reported (Laderach, 
2003). Knock-down of UCP2 expression was obtained by transfecting cells with a 
UCP2 small interfering (si) RNA having the following sequences: 5′-
ACAGUGAAUUUAAACGACAGCAGCU-3′ and 5′- 
AGCUGCUGUCGUUUAAAUUCACUGU-3′ and with a siRNA-CTRL 
(negative control): 5′- CAGUCGCGUUUGCGACUGG-3′ purchased from Life 
Technologies. Knock-down of PGC1-α expression was obtained by transfecting 
cells with a PGC1-α small interfering (si) RNA having the following sequences: 
5′-ACAGUGAAUUUAAACGACAGCAGCU-3′ and 5′- 
AGCUGCUGUCGUUUAAAUUCACUGU-3′ and with a siRNA-CTRL 
(negative control): 5′- CAGUCGCGUUUGCGACUGG-3′ purchased from Life 
Technologies.  Cells were transfected by siRNAs at a final concentration of 50 
nM using Lipofectamine 2000 (Life Technologies), according to the 
manufacturer's instructions. 
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RNA isolation and quantitative real-time PCR analysis 
Total RNA was extracted from cells using TRIZOL Reagent (Life Technologies) 
in accordance with the manufacturer’s instructions. Five micrograms of total RNA 
were reverse-transcribed at 37°C for 60 min in the presence of random hexamers 
and Moloney murine leukemia virus reverse transcriptase (Life Technologies). 
Transcripts were measured by real-time PCR using the SYBR Green assay 
(Applied Biosystems, Carlsbad, CA, USA) with a StepOne instrument (Applied 
Biosystems). PCR analysis was carried out using specific oligonucleotides for the 
genes listed in Table 2. The primers were designed with Primer3 version 0.4.0 
(http://frodo.wi.mit.edu/primer3/). All primer sets worked under identical 
quantitative PCR cycling conditions with similar efficiencies to obtain 
simultaneous amplification in the same run. The 2-ΔΔCT method for relative 
quantification of gene expression was used to determine mRNA expression levels. 
GAPDH gene expression was used as endogenous control to standardize mRNA 
expression. All reactions were performed in duplicate from three independent 
experiments. 
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Table 2. Sequences of primers used for qPCR analysis of autophagy- and ROS-related 
genes. 
 
ChIP experiments 
1% formaldehyde cross-linking and chromatin immunoprecipitations were 
performed as described in (Di Agostino, 2006; Valenti, 2011). The chromatin 
solution was immunoprecipitated with sheep anti-p53 Ab7 (Millipore, Billerica, 
MA, USA), rabbit anti-p50 (Santa Cruz Biotech. SC-7178), rabbit anti-p65 (Santa 
Cruz Biotech SC-372), or no antibody as negative control. The 
immunoprecipitations were performed using Pierce ChIP-grade Protein A/G 
magnetic beads  (Thermo Fisher Scientific, Rockford, IL, USA). Primers used for 
the amplification of the different regulatory regions are listed in Table 3. NF-κB 
p50 Region 2 consensus sequence on ATG12 promoter was selected from the 
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literature and NF-κB p50 Region 1, the consensus sequence was identified by 
MatInspector software (www.genomatix.de). The promoter occupancy was 
analyzed by RT-qPCR using the Fast SYBR Green assay (Applied Biosystems, 
Carlsbad, CA, USA) and the StepOne™ Real-Time PCR System (Applied 
Biosystems). Normalization was performed to the amount of input chromatin. 
 
Table 3. Sequences of primers used for ChIP analysis in the region1 and region2 of the 
atg12 promoter 
 
Immunoblot analysis 
Cells were harvested, washed in PBS, and re-suspended in lysis buffer in the 
presence of phosphatase and protease inhibitors (50 mM Tris–HCl pH 8, 150 mM 
NaCl, 1% Igepal CA-630, 0.5% Na-Doc, 0.1% SDS, 1 mM Na3VO4, 1 mM NaF, 
2.5 mM EDTA, 1 mM PMSF, and 1× protease inhibitor cocktail). After 
incubation on ice for 30 min, the lysates were centrifuged at 14,000 × g for 10 min 
at 4°C and the supernatant fractions were used for Western blot analysis. Protein 
concentration was measured by Bradford reagent (Pierce, Milan, Italy) using 
bovine serum albumin as a standard. Protein extracts (50 μg/lane) were resolved 
on a 12% SDS-polyacrylamide gel and electro-blotted onto PVDF membranes 
(Millipore, Milan, Italy). Membranes were blocked in 5% low-fat milk in TBST 
(50 mM Tris pH 7.5, 0.9% NaCl, 0.1% Tween 20) for 1 h at room temperature 
and probed overnight at 4°C with a mouse polyclonal anti-p53 (1:500) (Santa 
Cruz, #sc-263), rabbit monoclonal anti-LC3 (1:1,000) (Cell Signaling, #2775), 
rabbit polyclonal antiphospho(Ser15)Beclin1 (1:1,000) (Cell Signaling #13825) 
rabbit polyclonal anti-Beclin1 (1:1,000) (GeneTex, #GTX113039), rabbit 
monoclonal glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (1:1,000) (Cell 
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Signaling, #5174S), rabbit monoclonal anti-phospho (Thr172)AMPK (1:1,000) 
(Cell Signaling #2535), rabbit monoclonal anti-AMPK (1:1,000) (Cell Signaling 
#2603), mouse monoclonal anti-phospho (Thr389)p70S6K (1:1,000) (Cell 
Signaling #9206), rabbit monoclonal anti-p70S6K (1:1,000) (Cell Signaling 
#2708), rabbit polyclonal anti-SESN1 (1:1,000) (GeneTex #GTX116926), rabbit 
polyclonal anti-SESN2 (1:1,000) (GeneTex#118141), rabbit polyclonal anti-NF-
κB p50 (1:1,000) (Santa Cruz #sc-7178), rabbit polyclonal anti-NF-κB p65 
(1:1,000) (Santa Cruz #sc-372), mouse monoclonal anti-alpha-tubulin (1:2,500) 
(Oncogene #CP06), or rabbit monoclonal anti-phospho (Tyr705)STAT3 (1:1,000) 
(Cell Signaling #9131), goat polyclonal antiUCP2 (1:2,000) (Abnova #PAB7242) 
antibodies. Horseradish peroxidase conjugated anti-mouse or anti-rabbit IgGs 
(1:8,000 in blocking solution) (Upstate Biotechnology, Milan, Italy) were used as 
secondary antibodies. Immunodetection was carried out using chemiluminescent 
substrates (Amersham Pharmacia Biotech, Milan, Italy) and recorded using a 
HyperfilmECL (Amersham Pharmacia Biotech). ECL results were scanned and 
the amount of each protein band quantified using NIH Image J software 
(http://rsb.info.nih.gov/nihimage/). 
 
Immunoprecipitation assay 
Cell extracts were solubilized in lysis buffer with 150 mM Hepes pH 7.5, 300 mM 
NaCl, 1% Triton-X100, phosphatase and protease inhibitors. Cells were harvested 
and lysed by sonication in lysis buffer and cleared by centrifugation. Protein 
concentrations were determined by colorimetric assay (Bio-Rad, Hercules, CA, 
USA). For each immunoprecipitation, 1 microg of antibody and 1 microg of rabbit 
or sheep IgG (Santa Cruz Biotech) were used as controls. To immunoprecipitate, 
we used rabbit polyclonal anti-p50 (sc-7178) from Santa Cruz Biotech and sheep 
polyclonal anti-p53 Ab7 (PC35-1EA) from Millipore. 1 mg of pre-cleared extracts 
were diluted in lysis buffer containing 0.05% BSA and incubated with protein 
A/G-Agarose beads (Thermo Fisher Scientific, Rockford, IL, USA) and 
antibodies, under constant shaking at 4°C for 3 hours. Bead-bound 
immunocomplexes were rinsed with lysis buffer and eluted in 50 μl of SDS 
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sample buffer for Western blotting. Western blotting was performed using the 
following primary antibodies: mouse monoclonal p53 (DO1), GAPDH (Santa 
Cruz Biotech), rabbit polyclonal anti-NF- 0) (Santa Cruz #sc-372), 
rabbit polyclonal anti-p50 (sc-7178) and actin (Sigma) antibodies. Western blot 
analysis was performed with the aid of the enhanced chemiluminescence system 
(Thermo Fisher Scientific, Rockford, IL, USA) and the acquisition of the images 
by Uvitec technology (Eppendorf). 
 
Apoptosis assay 
Cells were seeded in 96-well plates (5× 10
3
 cells/well). Twenty-four hours later, 
cells were treated as indicated in the figure legends. At the end of the treatment, 
cells were fixed with 2% paraformaldehyde in PBS for 30 min at room 
temperature, washed twice with PBS and stained with annexin V/FITC (Bender 
MedSystem, Milan, Italy) in binding buffer (10 mM HEPES/NaOH pH 7.4, 
140mM NaCl, and 2.5mM CaCl2) for 10 min at room temperature in the dark. 
Cells were then washed with binding buffer and fluorescence was measured using 
a multimode plate reader (Ex485nm and Em535nm) (GENios Pro, Tecan, Milan, 
Italy). The values were normalized on cell proliferation by Crystal Violet assay. 
 
Monodansylcadaverine staining and autophagosome formation assay 
To quantify the induction of autophagy, cells were incubated with the fluorescent 
probe monodansylcadaverine (MDC; Sigma, Milan, Italy), accordingly with the 
guidelines for studying autophagy (Klionsky, 2016). MDC is a selective marker 
for acidic vesicular organelles, such as autophagic vacuoles. Briefly, cells were 
seeded in 96-well plates (5 × 10
3 
cells/well) and treated with various compounds 
as indicated in the figure legends. At the end of the treatments, cells were 
incubated in culture medium containing 50 μM MDC at 37°C for 15 min. Cells 
were then washed with Hanks buffer (20 mM Hepes pH 7.2, 10 mM glucose, 118 
mM NaCl, 4.6 mM KCl, and 1 mM CaCl2) and fluorescence was measured using 
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a multimode plate reader (Ex340nm and Em535nm) (GENios Pro, Tecan, Milan, 
Italy). The values were normalized for cell proliferation by Crystal Violet assay. 
 
Acridine orange staining and autolysosome detection 
Cells were seeded in a 24-well plate on glass cover-slips at a density of 6 x 
104/well. After 24 hours, cells were transfected with pRSUPER-p53 or with the 
empty pRSUPER vector by using Lipofectamine 2000 according to the 
manufacturer’s instructions. 48 hours after transfection cells were rinsed in 
phosphate buffer saline (PBS) and stained with 6 μg/ml acridine orange (AO). 
Cell images were captured using a fluorescence microscope Leica DM6000 (Leica 
Microsystem, Manheim, Germany) at 40× magnification and processed using 
Adobe Photoshop and NIH ImageJ software. To quantify autolysosome 
formation, cells transfected with pRSUPER-p53 vector or its negative control 
(pRSUPER) were stained with AO following the manufacturer's instructions. 
Quantification of autolysosomes was performed measuring the red/green 
fluorescence intensity ratio of AO staining (AO green fluorescence Ex485nm and 
Em535nm; AO red fluorescence Ex430nm and Em590nm) with a multimode plate 
reader (GENios Pro, Tecan, Milan, Italy). Values were normalized on cell 
proliferation by crystal violet assay. 
 
LC3-GFP and lysosome co-localization analysis 
Cells were seeded in a 24-well plate on glass cover-slips at a density of 6 x 
10
4
/well. After 24 hours, cells were co-transfected with pEGFP-LC3B and 
pRSUPER-p53 vector or with pEGFP-LC3B and the pRSUPER empty vector by 
using Lipofectamine 2000, according to the manufacturer’s instructions. 48 hours 
after transfection, lysosomes were stained with 50 nM Lysotracker-RED DN99 
(Life Technologies) and nuclei were stained with 0.1 μg/ml Hoechst (Life 
Technologies). Cells were than rinsed in PBS and fixed in 4% (w/v) 
paraformaldehyde. Cover-slips were mounted over slides in AF1 medium (Dako). 
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Cell images were captured using a confocal laser-scanning fluorescence 
microscope Leica SP5 (Leica Microsystem, Manheim, Germany) at 63× 
magnification and processed using Adobe Photoshop and NIH Image J software. 
 
GEO expression data 
We used the publicly available data sets: GSE22358 (Gluck, 2012) and 
GSE31812 (Freed- Pastor, 2012). The data sets were analyzed by the Oncomine 
platform www.oncomine.org (Rhodes, 2004).  
 
Kaplan-Meier analysis 
Gene expression dataset raw data and survival information of 108 BCL patients 
with mutant TP53 gene were downloaded from GEO 
(http://www.ncbi.nlm.nih.gov/geo/) and the Kaplan-Meier analysis was performed 
by using the on-line tool www.kmplot.com (Gyorffy, 2010) where eight public 
datasets were considered. Gene expression profiles were performed by using 
Affymetrix HGU133A (GPL96) and HG-U133 Plus 2.0 (GPL570) microarrays 
were only considered. The latter are the most frequently used and have 22,277 
probe sets in common. To analyse the prognostic value of genes, the cohorts were 
divided into two groups according to the median (or upper/lower quartile) 
expression of gene signature considered. The two groups were compared in terms 
of relapse free survival (RFS) and distant metastasis free survival (DMFS). A 
survival curve was displayed, and the hazard ratio with 95% confidence intervals 
and logrank P value are calculated. P values < 0.05 were considered statistically 
significant. 
 
Analysis of ROS 
The non-fluorescent diacetylated 2,7-dichlorofluorescein (DCF-DA) probe 
(Sigma), which becomes highlyfluorescent upon oxidation, was used to evaluate 
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intracellular ROS production. Cells were plated in 96-well plates (5 × 10
3
 
cells/well) and treated with various compounds 24 h later, as indicated in the 
legends to the figures. Then, cells were incubated with 10μM DCF-DA for 15 min 
at 37 °C, and DCF fluorescence was measured (λexc 485 nm and λem 535 nm) in 
a multimode plate reader (GENios Pro, Tecan, Milan, Italy). Values were 
normalized on cell proliferation by the crystal violet assay.  
To evaluate mitochondrial superoxide (O2
•−
) production, cells were incubated at 
37 °C for 15 min in a culture medium supplemented with 1 μM non-fluorescent 
MitoSox Red probe (Molecular Probes, Invitrogen). Cells were w ashed with 
Hanks buffer (20 mM Hepes pH 7.2, 10 mM glucose, 118 mM NaCl, 4.6 mM 
KCl, and 1 mM CaCl2) and fluorescence was measured in a multimode plate 
reader (λexc 430 nm and λem 590 nm). The probe is live-cell permeant and is 
rapidly and selectively targeted to mitochondria where it becomes fluorescent 
after oxidation by O2
•−
. The usage of 430 ± 35 nm excitation wavelengths allowed 
us to selectively detect mitochondrial O2
•−
 and to strongly reduce the recognition 
of other oxidants (e.g., –OH, ONOO.−). Values were normalized on cell 
proliferation by the crystal violet assay. 
 
Mitotracker and MitoSox colocalization analysis 
Cells were seeded in a 24-well plate on glass coverslips at the density of 6 x 
10
4
/well. After 24 hours cells were co-transfected with plasmid expressing p53 
R175H and p53 R273H and its control (empty vector) by using Lipofectamine 
2000, according to the manufacturer’s instructions. 48 hours after transfection, 
mitochondria were stained with 50 nM Mitotracker (Life Technologies), MitoSox 
(Life Technologies) and nuclei were stained with 0.1 μg/ml Hoechst (Life 
Technologies). Cells were than rinsed in PBS and fixed in 4% (w/v) 
paraformaldehyde. Coverslips were mounted over slides in AF1 medium (Dako). 
Cell images were captured using a confocal laser-scanning fluorescence 
microscope Leica SP5 (Leica Microsystem, Manheim, Germany) at 63× 
magnification and processed using Adobe Photoshop and NIH ImageJ software. 
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Statistical analysis 
ANOVA (post hoc Bonferroni) analysis was performed by GraphPad Prism 5 
software. Student's  test (two-tailed) was also conducted. P value < 0.05 was 
indicated as statistically significant. Values are the means of three independent 
experiments (±SD). 
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7. DISCUSSION AND CONCLUSION 
Mutations in the TP53 gene occur in over 50% of the human cancers (Vousden, 
2002; Waddell, 2014) and most of them are missense mutations that result in the 
expression of mutant forms of p53, which acquire new biological properties 
referred as gain-of-function (GOF) that contribute to the induction and 
maintenance of cancer (Santoro, 2014). In many human tumors, p53 mutations are 
associated with high genomic instability, poor prognosis, poor response to 
chemotherapy and accelerated tumor recurrence (Ganci, 2013; Liu, 2012; 
Walerych, 2012). Different models have been proposed to explain the GOF 
activities of mutant p53, including binding and inactivation of the p53 family 
members p63 and p73; modulation of the activity of the transcription factors NF-
Y, E2F1, E2F4, p65 NF-κB, and vitamin D receptor (VDR); or the inactivation of 
the DNA damage sensor ataxia telangiectasia mutated (ATM) (Di Agostino, 2006; 
Strano, 2007; Valenti, 2015; Stambolsky, 2010). Recently, we have documented 
that the DNA damaging drug gemcitabine stabilized mutant p53 protein in cell 
nuclei inducing chemoresistance and the mutant-p53 dependent expression of cell 
cycle genes, as Cdk1 and CCNB1, resulting in a hyperproliferation effect (Fiorini, 
2015). This broad spectrum of molecular properties indicates that mutant p53 
proteins are involved in a plethora of different cellular pathways focused on 
cancer progression and aggressiveness. The high frequency of GOF mutations in 
the TP53 gene in cancer cells and the relevance of mutp53s in the clinical 
outcome of cancer patients have solicited worldwide scientists working in 
molecular oncology to deeply investigate the events associated to cancer 
progression driven by mutp53 proteins. Autophagy is a tightly regulated catabolic 
process of cellular self-digestion by which cellular components are targeted to 
lysosomes for their degradation. However, the role of autophagy in modulating 
cell death is highly dependent on the metabolic context and on the 
microenvironmental conditions in which the cells lie (Lorin, 2013). Key functions 
of autophagy are aimed to provide energy and metabolic precursors under 
conditions of starvation and to alleviate cellular stress removing damaged proteins 
and organelles, which are deleterious for cell survival. Therefore, autophagy 
appears to serve as a pro-survival stress response in most settings (Fiorini, 2013). 
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However, increasing evidence show the pivotal role of autophagy in cell death 
after treatment with anti-cancer drugs or under particular stressful conditions 
(Fiorini, 2015; Fulda and Kogel, 2015). Thus, despite the net effect of autophagy 
in cancer cells is highly contextual, substantial results describe that enforced over-
activation of autophagy can lead to excessive cellular self-digestion via the 
autophagosomal-lysosomal pathway determining autophagic cell death (also 
named cell death type II) (Galluzzi, 2012). The importance of autophagic cell 
death becomes evident by the consideration that it is able to bypass drug 
resistance, especially in apoptosis refractory tumors, offering new therapeutic 
options in overcoming cancer resistance mechanisms (Fulda and Kogel, 2015; 
Schonthal, 2009).  
The high mutation rate and the severe genomic instability are the most important 
features of the cancers expressing mutant p53 proteins (Soussi and Wiman, 2007). 
Reactive oxygen species are radicals, ions or molecules that have a single 
unpaired electron in their outermost shell of electrons and for this character, they 
are highly reactive. Mitochondria and peroxisomes are the major sites of cellular 
ROS generation (Danse, 2001; Ha, 2011) and while under normal physiological 
conditions, the intracellular levels of ROS are steadily maintained to prevent cells 
from damage, in cancer cells the high metabolic rate, inflammatory status or 
oncogene activity results in a high ROS levels compared to normal cells (Storz, 
1999). A great amount of studies has deeply unveiled the existence of a ROS-
mediated regulation in several cellular pathways (Liu and Storz, 2010) that sustain 
a plethora of biological events involved in tumor progression (Fiaschi and 
Chiarugi, 2012).  
In this thesis we report new mechanisms by which GOF mutp53 proteins sustain 
aggressiveness of human cancer through a sophisticate dysregulation of some 
signaling pathways involved in the response of energy stresses and in the 
maintaining of ROS homeostasis in cancer cells. We clearly demonstrated that 
GOF mutant p53 proteins are able to orchestrate a plethora of events addressed to 
counteract autophagy in the various phases of the process, thus contributing to 
inhibit apoptosis and to sustain the oncogenic activity of mutant p53. Notably, we 
showed that mutant p53 inhibits AMPK-signaling by down-regulating Sestrin1/2 
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expression and stimulates mTOR signaling, resulting in a strong inhibition of 
autophagy in cancer cells. As paradigma of the transcriptional regulation of 
mutant p53 in autophagic process we unveiled that it is able to interact with the 
p50 NF-κB subunit onto the atg12 promoter inhibiting its expression and 
contributing in the repression of the autophagic machinery. Concerning the 
metabolic regulation of mutant p53 in tumors, we further demonstrated that 
PKM2 expression and its Tyr105 phosphorylated form were strongly induced by 
mTOR stimulation. Our data are consistent with the study of Zhang et al., which 
documented that mutant p53 was responsible for the raise of the glycolytic rate in 
cancer cells (Zhang, 2013), and with the study of Hitosugi et al. which revealed 
that mutation at Tyr105 of PKM2 determined both the decrease of the cellular 
proliferation and the increase of oxidative phosphorylation and lactate production 
(Hitosugi, 2009). Altogether these findings strongly suggest the involvement of 
PKM2 regulation on lactate secretion and on the glycolytic cancer metabolism 
supported by mutant p53 activity. In addition, we showed that mutant p53 was 
able to induce mTOR-dependent STAT3 pathway which has been already 
described to stimulate the Warburg effect (Li, 2015) and cancer progression (Yu, 
2014), and to inhibit autophagy by down-regulating LC3 gene (Gong, 2014). 
Interestingly, we point out that cancer cells bearing endogenous mutant p53 are 
more sensitive to the mTOR inhibitor everolimus than cancer cells expressing 
wild-type p53 protein, providing a conceivable personalized therapy for cancer 
patients carrying GOF mutations of the TP53 gene. Our further unpublished data 
revealed that through the down-regulation of AMPK signaling, mutant p53 
proteins effectively contrast PGC-1α/UCP2 axis that is a key regulator of 
mitochondrial ROS homeostasis in the cells. As a consequence of the inhibition of 
these antioxidant players, we observed that mutant p53 enhances mitochondrial 
and cytosolic ROS production and hence oxidative stress, resulting in the 
stimulation of chemoresistance and proliferation of cancer cells. It is tempting to 
speculate about the existence of novel mechanisms by which GOF mutant p53 
proteins are able to orchestrate cancer cell proliferation, that we have found to be 
i) the inhibition of autophagy-apoptosis axis and ii) by enhancing oxidative stress, 
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which might provide new therapeutic opportunity to treat patients bearing mutant 
TP53 gene. 
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